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ABSTRACT 
 Patients with obesity develop a metabolic heart disease (MHD) of unclear 
mechanisms and limited therapeutic options. MHD is characterized by left-ventricular 
hypertrophy and impaired ventricular relaxation and is associated with cardiac lipid 
accumulation, oxidative stress and impaired energetics. Mitochondria play a critical role 
in cardiac metabolism and mitochondrial dysfunction results in a pathologic decrease in 
ATP production and increase in reactive oxygen species (ROS) generation. I 
hypothesized that nutrient excess and cardiac lipid accumulation impair 
mitochondrial function and cause cardiac remodeling through mitochondrial 
oxidative stress. 
 Mice overexpressing fatty acid transport protein 1 (FATP1) in cardiomyocytes 
have increased uptake and use of cardiac lipids and develop MHD. I observed that 
FATP1 mice have increased cardiac diacylglycerols and PKC activation and decreased 
mitochondrial biogenesis, size, and oxygen consumption with unchanged ATP synthesis 
and ROS production. Overexpression of the antioxidant enzyme catalase in mitochondria 
	  	   vi 
(mCAT) does not attenuate MHD in FATP1 mice. This suggests that FATP1-driven 
cardiac lipid accumulation leads to compensated downregulation of mitochondrial 
function without oxidant overproduction. 
Mice fed a high fat, high sucrose (HFHS) diet have myocardial oxidative stress 
and develop MHD. I observed that cardiac mitochondria of HFHS-fed mice have 
increased ROS production and decreased ATP synthesis and oxygen consumption. 
HFHS-fed mCAT mice do not develop mitochondrial dysfunction or cardiac remodeling, 
suggesting that mitochondrial ROS may mediate HFHS-driven mitochondrial dysfunction 
and MHD. 
Mice with partial loss of the mitochondrial transporter ABCB10 exhibit cardiac 
oxidative stress leading to impaired recovery from ischemic injury. I generated mice with 
cardiomyocyte-specific ABCB10 deletion and observed that ABCB10 loss decreases 
mitochondrial oxygen consumption and increases ROS production without altering ATP 
synthesis or affecting cardiac structure and function. After HFHS feeding, mice with 
heterozygous loss of cardiomyocyte ABCB10 have exaggerated MHD and increased 
mortality, suggesting a protective role of ABCB10 in MHD induced by HFHS diet. 
In summary, cardiac lipid accumulation leads to transcriptional downregulation of 
mitochondrial respiration, while dietary fat and sugar excess leads to mitochondrial 
dysfunction and cardiac remodeling driven by mitochondrial oxidative stress and 
exacerbated by loss of ABCB10. This study suggests that oxidant-driven mitochondrial 
dysfunction plays a key role in MHD.  
	  	   vii 
TABLE OF CONTENTS 
 
TITLE	  PAGE	  .................................................................................................................................	  i	  
COPYRIGHT	  PAGE	  ....................................................................................................................	  ii	  
READER’S	  APPROVAL	  PAGE	  ................................................................................................	  iii	  
ACKNOWLEDGMENTS	  ...........................................................................................................	  iv	  
ABSTRACT	  ...................................................................................................................................	  v	  
TABLE	  OF	  CONTENTS	  ...........................................................................................................	  vii	  
LIST	  OF	  TABLES	  .....................................................................................................................	  xii	  
LIST	  OF	  FIGURES	  ...................................................................................................................	  xiii	  
LIST	  OF	  ABBREVIATIONS	  ...................................................................................................	  xix	  
Chapter	  1:	  Introduction	  ........................................................................................................	  1	  
1.1	   Obesity	  and	  Heart	  Failure	  ...................................................................................................	  1	  
1.2	   Metabolic	  Heart	  Disease:	  Overview	  .................................................................................	  3	  
1.3	   Lipids:	  Use,	  Disuse,	  and	  Regulation	  ..................................................................................	  4	  
1.4	   Mitochondria	  in	  the	  Heart	  ...................................................................................................	  6	  
1.5	   Mitochondrial	  Dysfunction	  and	  Oxidative	  Stress	  ........................................................	  9	  
1.6	   Animal	  Models	  of	  Lipotoxicity	  and	  MHD	  .....................................................................	  10	  
1.7	   Hypothesis	  .............................................................................................................................	  11	  
1.8	   Specific	  Aims	  .........................................................................................................................	  11	  
	  	   viii 
Chapter	  2:	  Materials	  And	  Methods	  ..................................................................................	  12	  
2.1	   Experimental	  Animals	  .......................................................................................................	  12	  
2.2	   Lipidomic	  Analysis	  ..............................................................................................................	  12	  
2.3	   Immunoblotting	  ...................................................................................................................	  13	  
2.4	   PCR	  Array	  and	  RT-­‐PCR	  .......................................................................................................	  13	  
2.5	   Electron	  Micrographs	  .........................................................................................................	  14	  
2.6	   Mitochondrial	  Isolation	  .....................................................................................................	  15	  
2.7	   Mitochondrial	  Oxygen	  Consumption	  Rate	  ..................................................................	  15	  
2.8	   Mitochondrial	  ATP	  Synthesis	  Rate	  ................................................................................	  16	  
2.9	   Complex	  II	  Activity	  Assay	  ..................................................................................................	  17	  
2.10	   Mitochondrial	  ROS	  Production	  Rate	  ..........................................................................	  17	  
2.11	   Echocardiographic	  Measurements	  .............................................................................	  18	  
2.12	   Statistical	  Analysis	  ............................................................................................................	  18	  
Chapter	  3:	  Mitochondrial	  Remodeling	  in	  Mice	  with	  Cardiomyocyte-­‐Specific	  
Lipid	  Overload	  ........................................................................................................................	  19	  
3.1	   Rationale	  ................................................................................................................................	  19	  
3.2	   Experiments	  ..........................................................................................................................	  20	  3.2.1	   Long-­‐chain	  diacylglycerol	  species	  are	  increased	  in	  FATP1	  hearts	  ..........................	  20	  3.2.2	   Increased	  PKC	  phosphorylation,	  decreased	  AKT	  phosphorylation,	  and	  decreased	  expression	  of	  CREB	  and	  PGC1α	  in	  FATP1	  hearts	  .....................................................	  21	  3.2.3	   FATP1	  hearts	  have	  decreased	  PPARα	  and	  mitochondrial	  fusion	  gene	  expression	  ........................................................................................................................................................	  31	  
	  	   ix 
3.2.4	   Increased	  lipid	  accumulation	  and	  altered	  mitochondrial	  morphology	  in	  FATP1	  hearts	   40	  3.2.5	   Complex	  II-­‐driven	  oxygen	  consumption	  is	  decreased	  in	  FATP1	  cardiac	  mitochondria	  with	  preserved	  ATP	  production	  ...............................................................................	  48	  3.2.6	   FATP1	  hearts	  have	  decreased	  mitochondrial	  complex	  II	  transcript,	  protein,	  and	  activity	  ...............................................................................................................................................................	  48	  3.2.7	   ROS	  production	  is	  unchanged	  from	  FATP1	  cardiac	  mitochondria	  and	  lack	  of	  protective	  effect	  of	  catalase	  overexpression	  in	  FATP1	  mice	  .....................................................	  52	  
3.3	   Discussion	  ..............................................................................................................................	  57	  3.3.1	   Structural	  mitochondrial	  remodeling	  ..................................................................................	  60	  3.3.2	   Functional	  mitochondrial	  remodeling	  .................................................................................	  61	  3.3.3	   Remodeling	  of	  the	  lipid	  pool	  and	  DG-­‐mediated	  signaling	  ...........................................	  62	  3.3.4	   Role	  of	  mitochondrial	  ROS	  ........................................................................................................	  63	  3.3.5	   Conclusion	  ........................................................................................................................................	  64	  
Chapter	  4:	  High	  Fat	  High	  Sucrose	  Diet	  Increases	  Mitochondrial	  Oxidant	  
Generation	  to	  Cause	  Mitochondrial	  Dysfunction	  and	  Cardiac	  Remodeling	  ......	  66	  
4.1	   Rationale	  ................................................................................................................................	  66	  
4.2	   Experiments	  ..........................................................................................................................	  67	  4.2.1	   HFHS	  diet	  increases	  cardiac	  mitochondrial	  ROS	  production	  .....................................	  67	  4.2.2	   HFHS	  diet	  impairs	  mitochondrial	  function	  in	  the	  heart	  ...............................................	  67	  4.2.3	   HFHS-­‐induced	  mitochondrial	  dysfunction	  is	  affected	  by	  mouse	  housing	  conditions	  ........................................................................................................................................................	  71	  4.2.4	   HFHS	  diet	  leads	  to	  a	  decrease	  in	  cardiac	  mitochondrial	  complex	  II	  activity	  ......	  71	  
	  	   x 
4.2.5	   HFHS-­‐fed	  mice	  have	  unchanged	  cardiac	  mitochondrial	  biogenesis,	  structure,	  and	  protein	  expression	  ..............................................................................................................................	  77	  4.2.6	   HFHS-­‐induced	  cardiac	  mitochondrial	  dysfunction	  is	  partially	  corrected	  in	  reducing	  environment	  in	  vitro	  ...............................................................................................................	  77	  4.2.7	   Overexpression	  of	  catalase	  in	  mitochondria	  prevents	  HFHS-­‐induced	  cardiac	  mitochondrial	  dysfunction	  .......................................................................................................................	  87	  4.2.8	   Overexpression	  of	  mitochondrial	  catalase	  prevents	  HFHS-­‐induced	  cardiac	  remodeling	  ......................................................................................................................................................	  87	  
4.3	   Discussion	  ..............................................................................................................................	  95	  4.3.1	   Mitochondria	  as	  a	  source	  of	  ROS	  ............................................................................................	  97	  4.3.2	   Mitochondria	  as	  a	  target	  of	  ROS	  .............................................................................................	  97	  4.3.3	   Roles	  in	  cardiac	  remodeling	  .....................................................................................................	  98	  4.3.4	   Housing	  effects	  on	  mitochondrial	  dysfunction	  ................................................................	  99	  4.3.5	   Differences	  from	  FATP1	  overexpression	  .........................................................................	  100	  
Chapter	  5:	  Loss	  of	  ABCB10	  in	  Cardiomyocytes	  Impairs	  Cardiac	  Mitochondrial	  
Function	  and	  Promotes	  Diet-­‐Induced	  Cardiac	  Remodeling	  ................................	  102	  
5.1	   Rationale	  ..............................................................................................................................	  102	  
5.2	   Experiments	  ........................................................................................................................	  103	  5.2.1	   Generating	  cardiomyocyte-­‐specific	  ABCB10+/-­‐	  and	  ABCB10-­‐/-­‐	  mice	  ...............	  103	  5.2.2	   CM-­‐specific	  loss	  of	  ABCB10	  leads	  to	  cardiac	  mitochondrial	  dysfunction	  ..........	  103	  5.2.3	   CM-­‐specific	  loss	  of	  ABCB10	  increases	  mitochondrial	  ROS	  production	  without	  altering	  antioxidant	  gene	  expression	  ...............................................................................................	  108	  5.2.4	   CM-­‐specific	  loss	  of	  ABCB10	  does	  not	  affect	  cardiac	  structure	  or	  function	  .......	  108	  
	  	   xi 
5.2.5	   CM-­‐ABCB10+/-­‐	  have	  decreased	  survival	  on	  HFHS	  diet	  ............................................	  114	  5.2.6	   CM-­‐ABCB10+/-­‐	  mice	  have	  exaggerated	  diet-­‐induced	  cardiac	  hypertrophy	  ....	  114	  5.2.7	   CM-­‐ABCB10+/-­‐	  have	  exaggerated	  diet-­‐induced	  diastolic	  dysfunction	  ..............	  119	  5.2.8	   CM-­‐ABCB10+/-­‐	  have	  similar	  mitochondrial	  dysfunction	  and	  ROS	  production	  after	  HFHS	  diet	  ...........................................................................................................................................	  119	  
5.3	   Discussion	  ............................................................................................................................	  127	  5.3.1	   ABCB10:	  Structure,	  function,	  and	  expression	  ................................................................	  127	  5.3.2	   Decreased	  survival	  in	  HFHS-­‐fed	  CM-­‐ABCB10+/-­‐	  mice	  ..............................................	  128	  5.3.3	   Role	  of	  ABCB10	  in	  response	  to	  HFHS	  ................................................................................	  129	  
BIBLIOGRAPHY	  ...................................................................................................................	  131	  
CURRICULUM	  VITAE	  ..........................................................................................................	  146	  	  
	   	  
	  	   xii 
LIST OF TABLES 
Table 1: Transcript fold change of PPAR target genes by PCR array. N=2 ..................... 39	  	  
  
	  	   xiii 
LIST OF FIGURES 
Figure 1. Mechanisms of systolic and diastolic heart failure. ............................................. 2	  
Figure 2. The electon transport chain power mitochondrial respiration. ............................ 7	  
Figure 3. FATP1 mice have cardiac hypertrophy. ............................................................ 22	  
Figure 4. FATP1 mice have cardiac diastolic dysfunction. .............................................. 23	  
Figure 5. Isolated FATP1 hearts have severe diastolic dysfunction. ................................ 24	  
Figure 6. Isolated FATP1 hearts have an increase in long-chain diacylglycerols. ........... 25	  
Figure 7. FATP1 hearts have no change in acylcarnitine content. ................................... 26	  
Figure 8. FATP1 hearts have no change in ceramide content. ......................................... 27	  
Figure 9. FATP1 hearts have no change in sphingomyelin content. ................................ 28	  
Figure 10. FATP1 hearts have a decrease in lipid metabolism genes. ............................. 29	  
Figure 11. FATP1 mice have no change in plasma ceramide or sphingomyelin content. 30	  
Figure 12. FATP1 hearts have increased PKC phosphorylation. ..................................... 32	  
Figure 13. FATP1 hearts have increased phosphorylation of PKC α and PKC δ, but no 
change in PKC ε. ....................................................................................................... 33	  
  34	  
Figure 14. FATP1 hearts have decreased AKT phosphorylation. .................................... 34	  
Figure 15. FATP1 hearts have decreased CREB transcript. ............................................. 35	  
Figure 16. FATP1 hearts have decreased CREB protein expression. ............................... 36	  
Figure 17. FATP1 hearts have decreased PGC1α transcript. ........................................... 37	  
Figure 18. FATP1 hearts have decreased PPARα, MFN1, MFN2, and OPA1 transcript. 38	  
Figure 19. FATP1 hearts have decreased MFN1, MFN2, and OPA1 protein expression. 41	  
	  	   xiv 
Figure 20. FATP1 hearts have altered mitochondrial morphology on electron 
micrographs. .............................................................................................................. 42	  
Figure 21. FATP1 hearts have increased lipid droplets on electron micrographs. ........... 43	  
Figure 22. FATP1 hearts have increased decreased mitochondrial size on electron 
micrographs. .............................................................................................................. 44	  
Figure 23. FATP1 hearts have increased debris accumulation on electron micrographs. 45	  
Figure 24. FATP1 hearts have unchanged mitochondrial volume density on electron 
micrographs. .............................................................................................................. 46	  
Figure 25. FATP1 hearts have unchanged mitochondrial mass by immunoblot. ............. 47	  
Figure 26. Mitochondria from FATP1 hearts exhibit unchanged complex I-driven oxygen 
consumption. ............................................................................................................. 49	  
Figure 27. Mitochondria from FATP1 hearts exhibit decreased complex II-driven oxygen 
consumption. ............................................................................................................. 50	  
Figure 28. Mitochondria from FATP1 hearts exhibit unchanged ATP synthesis rates. ... 51	  
Figure 29. Mitochondria from FATP1 hearts exhibit a decrease in SDHB transcript. ..... 53	  
Figure 30. Mitochondria from FATP1 hearts exhibit a decrease in SDHB protein 
expression. ................................................................................................................ 54	  
Figure 31. Mitochondria from FATP1 hearts exhibit a decrease in complex II activity. . 55	  
Figure 32. Mitochondria from FATP1 hearts exhibit unchanged mitochondrial H2O2 
production. ................................................................................................................ 56	  
Figure 33. FATP1xmCAT mice show no change in cardiac hypertrophy. ...................... 58	  
Figure 34. FATP1xmCAT mice show no change in cardiac diastolic dysfunction. ......... 59	  
	  	   xv 
Figure 35. Model of effect of FATP1 overexpression on mitochondrial structure and 
function. .................................................................................................................... 65	  
Figure 36. Hearts of HFHS-fed mice have an increase in mitochondrial H2O2 production.
................................................................................................................................... 68	  
Figure 37. Hearts of HFHS-fed mice have a decrease in mitochondrial oxygen 
consumption with complex II substrate. ................................................................... 69	  
Figure 38. Mitochondria from HFHS-fed mice have unchanged oxygen consumption with 
complex I substrates. ................................................................................................. 70	  
Figure 39. Mitochondria from HFHS-fed mice have decreased ATP production. ........... 72	  
Figure 40. Mitochondria from mice fed HFHS for 1 month have decreased oxygen 
consumption. ............................................................................................................. 73	  
Figure 41. Mice in IVC do not develop HFHS-induced decrease in oxygen consumption.
................................................................................................................................... 74	  
Figure 42. Mice in IVC do not develop HFHS-induced decrease in ATP synthesis. ....... 75	  
Figure 43. Hearts of HFHS-fed mice have a decrease in complex II activity. ................. 76	  
Figure 44. Hearts of HFHS-fed mice have an early increase in PGC1α transcript. ......... 78	  
Figure 45. Hearts of HFHS-fed mice have an early increase in fusion gene transcript. ... 79	  
Figure 46. Hearts of HFHS-fed mice by electron micrographs. ....................................... 80	  
Figure 47. Hearts of HFHS-fed mice may have slightly increased mitochondrial size. ... 81	  
Figure 48. Hearts of HFHS-fed mice may have unchanged mitochondrial density. ........ 82	  
Figure 49. Hearts of HFHS-fed mice have unchanged complex protein expression. ....... 83	  
	  	   xvi 
Figure 50. Decreased complex II-driven ATP synthesis in HFHS mitochondria is 
correctable in reducing conditions. ........................................................................... 84	  
Figure 51. Decreased complex I-driven ATP synthesis in HFHS mitochondria is not 
correctable in reducing conditions. ........................................................................... 85	  
Figure 52. Decreased complex II activity in HFHS mitochondria is correctable in 
reducing conditions. .................................................................................................. 86	  
Figure 53. mCAT prevents HFHS-induced complex I-driven H2O2 production. ............. 88	  
Figure 54. mCAT prevents HFHS-induced complex II-driven H2O2 production. ........... 89	  
Figure 55. mCAT prevents HFHS-induced complex I-driven decrease in ATP synthesis.
................................................................................................................................... 90	  
Figure 56. mCAT prevents HFHS-induced complex II-driven decrease in ATP synthesis.
................................................................................................................................... 91	  
Figure 57. mCAT prevents HFHS-induced complex II-driven decrease in oxygen 
consumption. ............................................................................................................. 92	  
Figure 58. mCAT prevents HFHS-induced oxidative modifications of complex II subunit 
B. ............................................................................................................................... 93	  
Figure 59. mCAT prevents HFHS-induced increase in cardiac total wall thickness. ....... 94	  
Figure 60. mCAT prevents HFHS-induced decrease in ventricular relaxation velocity. . 96	  
Figure 61. Hearts of CM-Abcb10-/- mice have decreased Abcb10 transcript. ............... 104	  
Figure 62. CM-ABCB10-/- hearts have decreased complex I-driven oxygen consumption.
................................................................................................................................. 105	  
	  	   xvii 
Figure 63. CM-ABCB10-/- hearts have unchanged complex II-driven oxygen 
consumption. ........................................................................................................... 106	  
Figure 64. CM-ABCB10-/- hearts have unchanged ATP synthesis. .............................. 107	  
Figure 65. CM-ABCB10-/- hearts have unchanged mitochondrial biogenesis and fusion 
gene expression. ...................................................................................................... 109	  
Figure 66. CM-ABCB10-/- hearts have increased complex I-driven ROS production. . 110	  
Figure 67. CM-ABCB10-/- hearts have unchanged antioxidant gene transcript. ........... 111	  
Figure 68. CM-ABCB10+/- and CM-ABCB10-/- mice have unchanged cardiac structure.
................................................................................................................................. 112	  
Figure 69. CM-ABCB10+/- and CM-ABCB10-/- mice have unchanged cardiac function.
................................................................................................................................. 113	  
Figure 70. CM-ABCB10+/- mice gain similar weight on HFHS diet. ........................... 115	  
Figure 71. CM-ABCB10+/- mice have increased mortality on HFHS diet. ................... 116	  
Figure 72. CM-ABCB10+/- mice have increased cardiac wall thickness after HFHS diet.
................................................................................................................................. 117	  
Figure 73. CM-ABCB10+/- mice may have increased heart weight after HFHS diet. .. 118	  
Figure 74. CM-ABCB10+/- mice have decreased diastolic relaxation velocity after HFHS 
diet. .......................................................................................................................... 120	  
Figure 75. WT and CM-ABCB10+/- mice have unchanged systolic function after HFHS 
diet. .......................................................................................................................... 121	  
Figure 76. CM-ABCB10+/- mice have increased mitochondrial ROS production with 
complex I substrates. ............................................................................................... 122	  
	  	   xviii 
Figure 77. CM-ABCB10+/- mice have increased mitochondrial ROS production with 
complex II substrates. ............................................................................................. 123	  
Figure 78. CM-ABCB10+/- mice have a decrease in state III oxygen consumption with 
complex II substrates. ............................................................................................. 124	  
Figure 79. CM-ABCB10+/- mice have a similar HFHS-induced decrease in ATP 
synthesis with complex I substrates. ....................................................................... 125	  
Figure 80. CM-ABCB10+/- mice have a similar HFHS-induced decrease in ATP 
synthesis with complex II substrates. ...................................................................... 126	  	  
  
	  	   xix 
LIST OF ABBREVIATIONS 	  ABCB10	   ATP-­‐Binding	  Cassette	  B10	  AC	   	   Acylcarnitine	  ACS	   	   Acyl-­‐CoA	  synthase	  ADP	   	   Adenosine	  diphosphate	  ATP	   	   Adenosine	  triphosphate	  BMI	   	   Body	  mass	  index	  CER	   	   Ceramide	  CPT	   	   Carnitine	  Palmitoyltransferase	  CREB	   	   Cyclic	  AMP	  responsive	  element	  binding	  protein	  DG	   	   Diacylglycerol	  DGAT	   	   diglyceride	  acyltransferase	  EM	   	   Electron	  micrographs	  ETC	   	   Electron	  transport	  chain	  FA	  	   	   Fatty	  acids	  FA-­‐CoA	   Fatty	  acyl-­‐CoA	  FATP1	  	   Fatty	  acid	  transport	  protein	  1	  HF	   	   Heart	  failure	  HFpEF	  	   Heart	  failure	  with	  preserved	  ejection	  fraction	  HFrEF	  	   Heart	  failure	  with	  reduced	  ejection	  fraction	  LPL	   	   Lipoprotein	  lipase	  
	  	   xx 
mCAT	   	   Mitochondrial	  catalase	  MHD	  	   	   Metabolic	  heart	  disease	  PCr	   	   Phosphocreatine	  PGC1α	  	   PPARγ	  coactivator-­‐1	  α	  PKC	   	   Protein	  kinase	  C	  PPARα	  	   Peroxisome	  proliferator-­‐activated	  receptor	  α	  ROS	   	   Reactive	  oxygen	  species	  SDHB	   	   Succinate	  dehydrogenase	  subunit	  B	  SM	   	   Sphingomyelin	  SOD	   	   Superoxide	  dismutase	  TG	   	   Triglyceride	  
	  	  
1 
Chapter 1: Introduction 
1.1 Obesity and Heart Failure  
Overweight and obesity affect two thirds of adults in the United States, and the 
role of obesity in human disease is staggering, with high body mass index (BMI) 
accounting for 16% of disease and showing clear associations with cardiovascular disease 
(Main, Rao, & O'Keefe, 2010). Obesity is a risk factor for heart failure (HF)(Kenchaiah 
et al., 2002), which is the most common cause of hospitalization for US adults over 65 
years and represents a dramatic healthcare burden, with a 5-year mortality rate of 50% 
and annual healthcare costs exceeding US$30 billion(Roger, 2013). 
HF is a clinical syndrome characterized by shortness of breath, fatigue, and fluid 
retention due to impaired cardiac function. In approximately half of HF patients, this is 
due to a decrease in the volume of blood pumped in each beat (ejection fraction, or EF), 
which occurs in approximately 50% of patients, and is known as heart failure with 
reduced ejection fraction (HFrEF). However, nearly half of HF patients have a preserved 
ejection fraction, (HFpEF), which is associated with a similar pattern of morbidity, 
mortality, and healthcare costs (K. Sharma & Kass, 2014). In these patients, cardiac 
dysfunction is characterized by an increase in left ventricular mass due to increased 
cardiomyocyte size, termed cardiac hypertrophy, and a stiffening, or decrease in the rate 
of relaxation of the left ventricle, known as diastolic dysfunction (Figure 1). 
A number of studies have shown that obesity is associated with increased risk of 
HF (particularly HFpEF) even in the absence of comorbidities such as coronary artery   
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Figure 1. Mechanisms of systolic and diastolic heart failure.  
Heart failure with reduced ejection fraction (left) is a defect in cardiac contractility (systole), while heart 
failure with preserved ejection fraction is a defect of cardiac relaxation and filling (diastole). Adapted from 
connecttoresearch.org 
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disease, pericardial disease, valvular disease, and congenital heart disease(Lavie et al., 
2013; Lavie, Milani, & Ventura, 2009). This suggests that nutrient excess may have 
direct effects on the heart. The mechanism of obesity-induced cardiac remodeling, termed 
metabolic heart disease (MHD) is unknown. 
1.2 Metabolic Heart Disease: Overview 
While the mechanisms leading to MHD are unknown, there are several 
noteworthy changes in the hearts of obese and diabetic patients of potential significance. 
It has been found that nutrient excess in the setting of obesity has profound effects on 
cardiac metabolism, with an increase in reliance on fatty acids (FA) and a decrease in 
glucose utilization for energetic substrate. This is associated with an increase in FA 
uptake, oxidation, and accumulation in the heart, with potentially deleterious 
consequences on cardiac structure and function, which has been termed lipotoxicity (See 
1.3: Lipids: Use, Disuse). Several studies have also shown that obese patients have 
impaired cardiac energetics, with decreased high-energy phosphate metabolism and 
diminished reserves of phosphocreatine (pCr)(Rider et al., 2013), the primary ATP 
transport and buffer system in the cardiomyocyte. It is well recognized that stable ATP 
production is critical for maintaining high-energy phosphate reserves, and that impaired 
energetics can lead to diastolic dysfunction due to the dependence of cardiomyocyte 
relaxation on ATP. The great majority (~90%) of the heart’s metabolism is aerobic, and 
occurs in mitochondria where sugar and lipid metabolites are converted for use in the 
electron transport chain to produce ATP. Thus, it has been hypothesized that 
mitochondrial dysfunction may potentially underlie the impaired energetics in MHD (See 
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1.5: Mitochondrial Dysfunction and Oxidative Stress). Finally, it is well recognized that 
obesity is associated with oxidative stress(Anderson et al., 2009), which can occur via 
overproduction and/or inefficient clearance of reactive oxygen species (ROS). ROS is 
produced from a number of intracellular sources, and one of the primary sources is from 
mitochondria. While small amounts of ROS can serve physiologically as signaling 
molecules, increased intracellular ROS levels can have pathological consequences (See 
1.5: Mitochondrial Dysfunction and Oxidative Stress). Taken together, it is conceivable 
that nutrient excess in the setting of obesity leads to changes in substrate metabolism and 
mitochondrial function to cause lipid accumulation, ATP depletion, and oxidative stress 
to contribute to the pathophysiology of MHD. 
1.3 Lipids: Use, Disuse, and Regulation 
The heart relies predominantly on FA for energetic substrate, with 60-90% of 
acetyl CoA coming from FA oxidation (Lopaschuk, Ussher, Folmes, Jaswal, & Stanley, 
2010). Short-chain FA are taken up passively through the sarcolemma while long-chain 
FA rely on transport proteins such as CD36, FATP1, FATP4, and FATP6 to enter the 
cardiomyocyte (Vork, Glatz, & van der Vusse, 1993). Once in the cytosol, FA are 
conjugated to form fatty acyl-CoAs (FA-CoA) by fatty acyl CoA synthase (ACS)(van der 
Vusse, van Bilsen, & Glatz, 2000) to prevent diffusion out of the cell. FA-CoA are then 
either esterified to triglycerides (TG) or converted to acylcarnitine to be imported into 
mitochondria by the carnitine acyltransferase shuttle (CPT1 and CPT2) to be re-
converted to FA-CoA and used for β-oxidation. In the healthy adult heart, 70-90% of FA 
are oxidized, and the remaining 10-30% are stored as TG (van der Vusse, Glatz, Stam, & 
	  	  
5 
Reneman, 1992). However, it has been noted that lipid metabolites such as ceramide, 
acylcarnitine, and diacylglycerol accumulate in the hearts of obese patients, and it is 
becoming increasingly clear from mouse studies that accumulation of lipids in the 
cardiomyocyte can cause MHD. 
A number of post-mortem case reports in the 19th century reported excessive 
epicardial fat accumulation and fatty degeneration of the myocardium in obese patients. It 
is now well-recognized that obese and diabetic patients accumulate lipids in the heart, 
and plasma FA levels negatively correlate with diastolic function (Leichman et al., 2006). 
In mice, genetic manipulations to increase cardiac FA uptake and utilization without 
altering whole body metabolism (See 1.6: Animal Models of Lipotoxicity and MHD) 
have supported the concept of cardiac lipotoxicity, showing that cardiomyocyte lipid 
overload is sufficient to cause pathologic cardiac remodeling. However, the mechanism 
by which cardiac FA excess leads to MHD remains poorly understood (Ghosh & 
Rodrigues, 2006; Main et al., 2010). Suggested mechanisms of lipotoxicity include direct 
toxicity of metabolites such as ceramide, changes in nuclear signaling driven by 
diacylglycerol, and/or mitochondrial dysfunction via cytosolic lipid excess. Ceramides 
can initiate apoptosis by stimulating cytochrome c release from mitochondria, and are 
increased in models of severe dilated cardiomyopathy. Diacylglycerols can interfere with 
the insulin-signaling cascade by activating protein kinase C, which can alter metabolic 
pathways and activate fibrotic signaling. Increased lipids can also directly lead to 
mitochondrial uncoupling, ROS production, and dysfunction. 
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Cardiac lipid metabolism is governed predominantly by expression level of 
metabolic enzymes, which is driven by the peroxisome proliferator-activated receptor α 
(PPARα)/PPARγ coactivator-1 α (PGC1α) transcriptional circuit. Increased FA 
availability leads to PPARα activation, which upregulates transcription of FA oxidation 
genes. This is closely tied to activation of PGC1α, which increases mitochondrial 
biogenesis and oxidative metabolism. Interestingly, mouse models of PPARα 
overexpression (Finck et al., 2002) and knockout (Campbell et al., 2002) both exhibit 
cardiac dysfunction, suggestive of a complex interplay between lipid metabolism and 
cardiac function at baseline and in response to stress. Cardiac hypertrophy is also 
associated with downregulation of PPARα signaling (Barger, Brandt, Leone, 
Weinheimer, & Kelly, 2000), although it is unclear whether that is adaptive or 
maladaptive. Finally, the effect of nutrient excess on cardiac PPARα signaling and its 
implications on mitochondrial biogenesis, structure, and function are not known.  
1.4 Mitochondria in the Heart 
The heart requires tremendous amounts of ATP (~6-30 kg per day) to fuel 
contraction (60-70%) and ion pumps (30-40%)(Gibbs, 1978). In order to supply such vast 
quantities, mitochondria occupy ~30% of cardiomyocyte volume. Mitochondrial ATP 
production relies on multi-protein enzyme complexes bound to the energy-transducing 
inner mitochondrial membrane (Figure 2). Electron transport chain (ETC) complexes I, 
III and IV utilize the downhill transfer of electrons from substrates (NADH and FADH2 
to complex I and II, respectively) to acceptor (the final being O2 to form H2O) in order to 
pump protons from the mitochondrial matrix into the inter-membrane space. The  
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Figure 2. The electon transport chain power mitochondrial respiration.  
Substrates enter the ETC at complexes I and II, and the downhill transfer of electrons generates energy to 
pump protons from the mitochondrial matrix into the inter-membrane space, creating an electrochemical 
gradient to drive the ATP synthase. In this process, oxygen is consumed, ATP is produced, and hydrogen 
peroxide is generated from electorn leak. 
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resulting proton gradient is used to drive ATP synthesis as protons passively re-enter the 
mitochondrial matrix through Complex V. One by-product of mitochondrial respiration is 
ROS production, as some electrons leak from the ETC and bind O2 to form O2*-, which is 
quickly dismutated by superoxide dismutase (SOD) into H2O2. Under normal conditions, 
mitochondrial ROS production accounts for 0.15% to 2% of oxygen consumption (Aon et 
al., 2012; Chance, Sies, & Boveris, 1979; Hoffman & Brookes, 2009), and H2O2 is 
neutralized into H2O by antioxidant mechanisms such as the enzyme catalase, the 
glutathione peroxidase/reductase system, and the thioredoxin peroxidase/reductase 
system. At normal physiological levels, H2O2 can act as a signaling molecule, but as the 
balance of production and neutralization is disrupted, it can become a damaging species 
(See 1.5: Mitochondrial Dysfunction and Oxidative Stress). 
Mitochondrial respiration is finely regulated at a number of levels, including 
transcript and protein expression of ETC proteins, post-translational modifications of 
ETC proteins, and coupling of the complexes to one another for efficient electron 
transduction. Additionally, it is becoming apparent that energetic capacity is affected by 
changes in mitochondrial architecture, as reflected by size, density, and morphology of 
mitochondria. These are tightly controlled by a mitochondrial life cycle of biogenesis, 
fusion/fission (Zorzano, Liesa, Sebastián, Segalés, & Palacín, 2010) and degradation 
(Dorn, 2013). Mitochondrial fusion is dependent on the proteins MFN1, MFN2, and 
OPA1, while mitochondrial fission is driven by DRP1. It has been noted in other cell 
types that dysregulation of mitochondrial dynamics (fusion/fission balance) can impair 
mitochondrial metabolism (Molina et al., 2009). Mitochondrial size and morphology may 
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be of significance in assessing nutrient-driven changes in mitochondrial function in the 
heart. 
1.5 Mitochondrial Dysfunction and Oxidative Stress 
Mitochondria can become dysfunctional through a number of mechanisms. 
Mitochondrial DNA mutations can alter expression and function of mitochondrial-
encoded proteins. Mitochondrial membrane lipid composition can be affected by the 
availability and quality of phospholipids such as cardiolipin, leading to changes in 
fluidity, protein super-complex formation, and proton leak. ROS can cause oxidative 
post-translational modification of ETC proteins to decrease mitochondrial respiration. As 
mitochondria become dysfunctional, more electrons are diverted away from the ETC, 
leaking primarily from complexes I and III, which increases mitochondrial ROS 
production (Murphy, 2009). This makes mitochondria both a source and target of ROS, 
leading to a cycle of ROS-induced ROS release. If not properly neutralized by 
mitochondrial and cytosolic scavenging systems, excess ROS result in oxidative stress 
with pathologic consequences. Oxidative stress in diabetes impairs myocardial function 
(Anderson et al., 2009; Tocchetti et al., 2012) and ROS are known to activate 
intracellular signaling to cause cardiac remodeling (Pimentel et al., 2006; Sawyer et al., 
2002). Attenuation of mitochondrial ROS has been shown to prevent heart failure in a 
number of animal models (Dai et al., 2009; Lee et al., 2010), suggesting a role for 
mitochondrial dysfunction and ROS production in cardiac pathology. The role of 
mitochondrial ROS in MHD warrants investigation. 
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1.6 Animal Models of Lipotoxicity and MHD 
Mouse models with genetic manipulation of cardiac FA metabolism have been 
used to study cardiac lipotoxicity. Hearts from mice overexpressing lipoprotein lipase 
(LpL), the enzyme responsible for facilitating uptake of plasma FA, accumulate lipids 
and exhibit dilation and systolic dysfunction (Yagyu et al., 2003). Overexpression of 
diacylglycerol acyl transferase (DGAT1), the enzyme responsible for synthesis of TG, 
leads to diastolic dysfunction, systolic dysfunction and cardiac fibrosis. Mice 
overexpressing acyl CoA synthase (ACS), the enzyme responsible for cytosolic 
conversion of FA to FA-CoA, accumulate TG in the heart and develop hypertrophy, with 
systolic and diastolic dysfunction (Chiu et al., 2001). Mice overexpressing fatty acid 
transport protein 1 (FATP1), the plasma membrane long-chain fatty acid transport protein 
have increased uptake and utilization of FA, and develop cardiac hypertrophy and 
diastolic dysfunction but show no change in systolic function (Chiu, 2005). The 
mechanism of cardiac lipid-mediated MHD remains poorly understood. 
Various models of dietary excess in rodents have been utilized to elucidate the 
effects of carbohydrate and/or fat intake on the heart. Sucrose feeding in rats causes 
cardiac hypertrophy, and fructose feeding in mice leads to hypertrophy and systolic 
dysfunction (Takimoto et al., 2005). Mice fed a high fat diet for 3 months exhibit cardiac 
hypertrophy and decreased contractile function, with a decrease in mitochondrial 
biogenesis (Ge et al., 2012) (Dong, Li, Sreejayan, Nunn, & Ren, 2007) (Zhang et al., 
2012). Published results from the Colucci lab show that mice fed a high fat and high 
sucrose (HFHS) diet develop MHD, with cardiac hypertrophy and diastolic dysfunction 
	  	  
11 
(Qin et al., 2012). This is associated with myocardial oxidative stress, and is prevented 
with an antioxidant polyphenol compound. The mechanism of diet-induced oxidant 
production and its role in MHD warrants investigation.  
1.7 Hypothesis 
Nutrient excess causes cardiac mitochondrial dysfunction and ROS overproduction 
leading to metabolic heart disease. 
1.8 Specific Aims 
1. Test the hypothesis that lipid accumulation in cardiomyocytes in the absence of 
systemic metabolic perturbation disrupts mitochondrial structure and function. 
2. Test the hypothesis that a high fat high sucrose diet increases mitochondrial ROS that 
play a pathologic role in mitochondrial dysfunction and cardiac remodeling. 
3. Test the hypothesis that ABCB10 minimizes mitochondrial oxidative stress and 
protects against mitochondrial dysfunction and cardiac remodeling induced by a high fat 
high sucrose diet. 
 
At the time of this writing, parts of this dissertation have been published in the following 
references: 
1. Elezaby A, Sverdlov AL, Tu VH, Soni K, Luptak I, Qin F, Liesa M, Shirihai OS, 
Rimer J, Schaffer JE, Colucci WS, Miller EJ. Mitochondrial remodeling in mice 
with cardiomyocyte-specific lipid overload. J Mol Cell Cardiol 2015;79;275-283. 
 
2. Sverdlov AL, Elezaby A, Behring JB, Bachschmid MM, Luptak I, Tu VH, Siwik 
DA, Miller EJ, Liesa M, Shirihai OS, Pimentel DR, Cohen RA, Colucci WS. High 
fat, high sucrose diet causes cardiac mitochondrial dysfunction due in part to 
oxidative post-translational modification of mitochondrial complex II. J Mol Cell 
Cardiol 2015;78;165-173.  	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Chapter 2: Materials And Methods 
2.1 Experimental Animals 
In chapter 3, cardiomyocyte-specific FATP1 (Chiu	   et	   al.,	   2005) and littermate 
control mice at 5-8 weeks of age were fed normal chow diet. Mice with systemic 
overexpression of catalase in mitochondria (mCAT) (Schriner	  et	  al.,	  2005) were crossed 
with FATP1 mice and echocardiographic studies were performed at 2-4 months of age. In 
chapter 4, male C57BL/6J mice and mice overexpressing catalase in mitochondria 
(mCAT) at 9 weeks of age were fed ad libitum either a control  (CD) chow diet (Research 
Diets, D09071703, 10% kcal lard, 0% sucrose) or a high fat high sucrose (HFHS) diet 
(Research Diets, D09071702, 58% kcal lard, 13% kcal sucrose). Feeding was continued 
for 1, 4 or 8 months. Similarly, in chapter 5, male and female cardiomyocyte-specific 
ABCB10+/- and ABCB10-/- mice were fed CD or HFHS diet for 4 months. The 
Institutional Animal Care and Use Committee at Boston University approved this study. 
2.2 Lipidomic Analysis 
Hearts were flash frozen and homogenized in PBS and protein concentration 
quantified by BCA protein assay. 50 µl of the homogenate or plasma was mixed 1:1 with 
methanol for protein precipitation. The supernatant was spiked with internal standards 
and was adjusted to 1 ml with 1:1 methanol/water solution for sphingomyelin (SM), 
ceramide (CER), diacylglycerol (DG) and acylcarnitine (AC). The samples were dried 
down and reconstituted in the 1:1 methanol/water solution. Samples were analyzed by 
liquid chromatography-tandem mass spectrometry (LC-MS/MS) as previously described 
	  	  
13 
(Fan	  et	  al.,	  2013) at the Metabolomics Facility of the Diabetic Cardiovascular Disease 
Center at Washington University.  
2.3 Immunoblotting 
Whole-heart protein lysates made from freeze-clamped hearts using lysis buffer 
(Hepes pH 7.4 (20 mM), β-Glycerol phosphate (50 mM), EGTA (2 mM), DTT (1 mM), 
NaF (10 mM), NaVO4 (1 mM), Triton-X 100 (1%), Glycerol (10%,) and 1 protease 
inhibitor complete mini tablet-EDTA free/20 ml (Roche)) were subjected to SDS-PAGE 
with protein content quantified using the Bradford method (Biorad).  Following transfer, 
nitrocellulose membranes were probed with primary antibodies to MFN1 (Neuromab), 
MFN2 (Sigma-Aldrich AV42420), OPA1 (BD Transduction 612606), phospho-PKCpan 
(Cell Signaling 9371), phospho-PKCα (Cell Signaling 06-822), total PKCα (EMD 05-
154), phospho-PKCδ (Cell Signaling 9376), total PKCδ (Santa Cruz 937), phospho-
PKCε (Santa Cruz sc12355), total PKCε (EMD 06-991), SDHB (Abcam ab110413), 
CREB (Pierce MA1-083), VDAC1 (Abcam ab15895), OXPHOS cocktail (Abcam 
ab110413), and GAPDH (Abcam ab9485), and visualized using horseradish peroxidase 
secondary antibodies with SuperSignal West chemiluinescence substrate and an enhanced 
chemiluminescence Fujifilm LAS-4000 imager or LI-COR secondary antibodies and the 
LICOR Odyssey IR imager.  Densitometry was quantified using Fujifilm Multigauge or 
Odyssey software. 
2.4 PCR Array and RT-PCR 
Frozen hearts were ground under liquid nitrogen and total RNA was extracted 
with the mirVana miRNA Isolation Kit (Applied Biosystems). Total RNA was treated 
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with DNAse before cDNA synthesis with the High Capacity RNA-to-cDNA Kit (Applied 
Biosystems). RT2 Profiler PCR arrays were performed per manufacturer instructions 
(SABiosciences) using the catalogued Mitochondria (PAMM-087Z), Mitochondrial 
Metabolism (PAMM-008Z) and PPAR Targets (PAMM-149Z) array configurations. 
Quanitative PCR was performed with TaqMan Universal PCR Master Mix and TaqMan 
primers (Applied Biosystems) specific for mouse PPARα (Mm00440939_m1), PGC1α 
(Mm01208835_m1), SDHB (Mm00458272_m1), MFN1 (Mm01289369_m1), MFN2 
(Mm00500120_m1), OPA1 (Mm00453873_m1), CREB1 (Mm00501604_m1), HSL 
(Mm00495359_m1), ATGL (Mm00503040_m1), DGAT1 (Mm00515643_m1), DGAT2 
(Mm00499536_m1), and GAPDH (4352339E) using the Applied Biosystems Step One 
Plus Real Time PCR Systems. Relative mRNA expression was normalized to GAPDH 
expression using the ΔΔCT method. 
2.5 Electron Micrographs  
Hearts were harvested, minced (4x4x1 mm), and placed in 2.5% 
glutaraldehyde/2.0% paraformaldehyde in 0.1 M cacodylate buffer fixative solution 
overnight. Specimens were then post-fixed in 1.0% osmium tetroxide in 0.15 M 
cacodylate buffer, dehydrated using a graded acetone series, and infiltrated and 
embedded with an epoxy resin at 65°	  overnight.  Specimens were thick sectioned (200 
nm) to search for areas of longitudinal fiber orientation, thin sectioned (75 nm) using a 
diamond knife onto a copper grid, stained with 4% aqueous uranyl acetate and lead 
citrate, and visualized using a CCD camera at 4,000x magnification. Image analysis was 
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performed blinded to genotype with free-hand tracing of mitochondria to estimate size 
using ImageJ and grid counting to estimate mitochondrial number per visual field. 
2.6 Mitochondrial Isolation  
Cardiac mitochondria were isolated as previously described (Liesa	  et	  al.,	  2011).  
In brief, hearts were harvested, washed and minced in ice-cold relaxation buffer (KCl 100 
mM, EGTA 5 mM, HEPES 5 mM pH 7.0 with KOH). Heart pieces were then 
homogenized in 2 ml of HES buffer (HEPES 5 mM, EDTA 1 mM, Sucrose 250 mM pH 
7.4) in a Teflon motor-drive homogenizer. The homogenized solution was centrifuged at 
500xg for 10 minutes at 4°C. The pellet was discarded and the supernatant was 
centrifuged at 9000xg for 15 minutes at 4°C. The mitochondrial pellet was resuspended 
in 50-100µl of HES buffer. Protein was quantified using bicinchoninic acid (BCA, 
Thermo Scientific) assay. 
2.7 Mitochondrial Oxygen Consumption Rate 
Oxygen consumption rates were monitored using a Seahorse XF24 oxygen flux 
analyzer as previously described (Liesa	  et	  al.,	  2011). Isolated mitochondria were loaded 
in a 24-well Seahorse plate on ice (5-10 µg per well) and 440 µl of ice-cold mitochondrial 
assay solution (MAS: 70 mM sucrose, 220 mM mannitol, 5 mM KH2PO4, 5 mM MgCl2, 
2 mM HEPES, 1 mM EGTA, 0.2% BSA fatty acid-free, pH 7.4) plus 10x substrates 
(complex I: 50 mM pyruvate and 50 mM malate; complex II: 50 mM succinate and 20 
µM rotenone in MAS) were added on top. The 4 sequential injection ports of the 
Seahorse cartridge contained the following: Port A- 50 µl of 10X substrate and 2.5 mM 
ADP, Port B- 55 µl of 20 µM oligomycin, Port C- 60 µl of 40 mM FCCP, Port D- 65 µl 
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of 40 µM antimycin A. State III was determined after port A injection, state IV after port 
B, and uncoupled after port C. Antimycin A was used as a control because it blocks the 
electron transport chain to minimize mitochondrial oxygen consumption. The results are 
reported as pmol oxygen/min/µg protein. 
2.8 Mitochondrial ATP Synthesis Rate 
ATP synthesis rates in isolated heart mitochondria were determined using the 
luciferin/luciferase-based ATP Bioluminescence Assay Kit CLS II (Roche) with minor 
modifications (Mansouri	   et	   al.,	   2006). In short, 10 µg of heart mitochondria were 
suspended in 75 µl buffer A (125 mM KCl, 10 mM Hepes, 5 mM MgCl2 and 2 mM 
K2HPO4, pH 7.44) to determine complex I- (pyruvate/ malate, 5 mM final) or complex II- 
(succinate, 5 mM final) driven ATP synthesis. Following standard practice, succinate-
driven ATP generation was measured in the presence of complex I inhibitor rotenone 
(0.5µM) to avoid the reverse electron transfer effect (Sahin	  et	  al.,	  2011). Measurements 
were repeated in the presence of oligomycin, an inhibitor of respiratory complex V to 
determine the rates of non-mitochondrial ATP production. The background of the assay 
was determined using mitochondria in the absence of substrates. The measurements for 
all samples were started simultaneously by adding 75 µl of luciferin/luciferase buffer 
containing 1 mM ADP (0.5 mM final). The initial slope of the increase in ATP-supported 
luciferase chemiluminescence was used to determine the rate of ATP production after 
subtraction of the background and non-mitochondrial values. Using an ATP standard 
provided in the kit, the slopes were converted to nmoles/min/mg protein. 
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2.9 Complex II Activity Assay 
 Complex II enzyme activity of isolated mitochondria was measured using 
microplate assay kit (Abcam/Mitosciences ab109908/MS241), as previously described (F.	   C.	   H.	   Li,	   Yen,	   Chan,	   &	   Chang,	   2012). In this assay kit, complex II was 
immunocaptured within the wells of the microplate. The production of ubiquinol by 
complex II was coupled to the reduction of the dye DCPIP (2,6-diclorophenolindophenol) 
and a decrease in its absorbance at 600 nm was measured spectrophotometrically. The 
assay was performed in the presence of succinate as a substrate. Enzymatic activity was 
normalized to mitochondrial protein concentration. 
2.10 Mitochondrial ROS Production Rate 
Mitochondrial H2O2 production was measured using the Amplex Ultra Red-
Horseradish peroxidase method (Invitrogen) as described previously (Muller	   et	   al.,	  2008) with minor modifications. This assay is based on the H2O2-dependent oxidation of 
nonfluorescent Amplex Ultra Red (50 µM) to fluorescent resorufin red by horseradish 
peroxidase (2 units/ml). In short, 10 µg mitochondria were suspended in 50 µl reaction 
buffer (125 mM KCl, 10 mM HEPES, 5 mM MgCl2, 2 mM K2HPO4, pH 7.44) to 
determine complex I- (pyruvate / malate, 5 mM) or complex II- (succinate, 5 mM) driven 
H2O2 production with and without inhibitors (rotenone 2 µM, antimycin A, 0.5 µM). 
Mitochondrial H2O2 production was measured after the addition of 50 µl of reaction 
buffer containing horseradish peroxidase and Amplex Ultra Red. Fluorescence was 
followed at an excitation wavelength of 545 nm and an emission wavelength of 590 nm 
for 20 minutes. The slope of the increase in fluorescence was converted to the rate of 
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H2O2 production with a standard curve. All of the assays were performed at 25°C, and 
results reported as pmoles/min/mg protein. 
2.11 Echocardiographic Measurements 
LV dimensions and systolic function were measured in non-anesthetized mice, 
and diastolic function was assessed by transmitral and tissue Doppler echocardiography 
in anesthetized mice as we have previously described (Qin	  et	  al.,	  2012). 
2.12 Statistical Analysis 
Results are presented as means ± SEM. Unpaired two-tailed t-tests were used for 
most experiments to determine statistical differences between two means and a P value < 
0.05 was considered significant. Statistical analysis of mitochondrial size utilized a non-
parametric Mann-Whitney test. Lipidomic data was analyzed using Welch’s t-test. 
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Chapter 3: Mitochondrial Remodeling in Mice with Cardiomyocyte-Specific 
Lipid Overload 
3.1 Rationale 
Metabolic heart disease (MHD) in patients with obesity and diabetes is 
characterized by cardiac hypertrophy and diastolic dysfunction. In MHD, increased 
cardiomyocyte uptake of circulating fatty acids (FAs) (Leichman	  et	  al.,	  2006) through 
cell surface transporters such as FATP1 (García-­‐Rúa	   et	   al.,	   2012) leads to lipid 
accumulation in the myocardium (S.	   Sharma	   et	   al.,	   2004). Cardiomyocyte lipid 
accumulation correlates with diastolic dysfunction (Leichman	   et	   al.,	   2006), impaired 
mitochondrial energetics (Neubauer,	  2007), and increased oxidative stress (Boudina	  &	  Abel,	   2007). The underlying mechanisms of MHD, including the direct effects of 
cardiomyocyte FAs on mitochondria, are not well described. It has been hypothesized 
that increased cardiomyocyte FA uptake could cause mitochondrial dysfunction (Boudina	   &	   Abel,	   2007;	   Goldberg,	   Trent,	   &	   Schulze,	   2012;	  Wende	   &	   Abel,	   2010). 
Possible mechanisms of mitochondrial dysfunction in MHD include respiratory chain 
uncoupling from ATP synthesis (Boudina	   &	   Abel,	   2006), increased reactive oxygen 
species (ROS) production (Wende	   &	   Abel,	   2010), altered biogenesis (Finck	   &	   Kelly,	  2007;	  Ren,	  Pulakat,	  Whaley-­‐Connell,	  &	  Sowers,	  2010), and/or impaired quality control (L.	  Chen	  &	  Knowlton,	  2011). However, elucidating the specific role of cardiomyocyte 
lipid excess in the pathogenesis of MHD can be confounded by systemic metabolic 
changes that occur with obesity (inflammation, insulin resistance, circulating factors) (M.	  C.	   Chan	  &	  Arany,	   2014;	  Ge	   et	   al.,	   2012). Thus, this study sought to test the effect of 
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increased cardiomyocyte FA accumulation on mitochondrial structure, function, and 
oxidant production in the absence of systemic metabolic perturbations.  
The hypothesis of this study was that excess cardiomyocyte FA uptake causes 
mitochondrial dysfunction due to lipid-mediated inhibition of mitochondrial biogenesis 
and/or energetic function. To address this hypothesis, mice with cardiomyocyte-specific 
overexpression of the fatty acid transport protein (FATP1) were used as a model of 
increased cardiomyocyte FA content in the absence of alterations in systemic 
metabolism. FATP1 mice exhibit increased cardiac FA uptake (4-fold) and utilization (2-
fold) and decreased glucose utilization (-50%) (Chiu	   et	   al.,	   2005). Their cardiac 
phenotype has been previously described (Chiu	   et	   al.,	   2005); they develop cardiac 
hypertrophy and diastolic dysfunction, and thus provide a model of MHD due to cardiac 
lipid overload. The goals of this study were to 1) determine the effects of FATP1-driven 
lipid excess on cardiomyocyte mitochondrial structure, function, and oxidant production, 
and 2) elucidate the mechanisms responsible for MHD in FATP1 hearts by examining 
toxic lipid accumulation, lipid-driven transcriptional regulation, and oxidative stress on 
mitochondrial structure and energetic function.  
3.2 Experiments 
3.2.1 Long-chain diacylglycerol species are increased in FATP1 hearts 
FATP1 functions to increase the intracellular accumulation of circulating long-
chain FAs, and its overexpression in the cardiomyocyte leads to cardiac hypertrophy 
(Figure 3) and diastolic dysfunction (Figure 4, Figure 5) (Chiu	  et	  al.,	  2005). These long-
chain FAs can then be metabolized or stored. Several lipid metabolites such as ceramide 
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(CER), acylcarnitine (AC), and diacylglycerol (DG) can function as signaling molecules 
and contribute to lipotoxicity (Goldberg	   et	   al.,	   2012), but the effect of FATP1 
overexpression on these lipid classes is not known. Therefore, we determined the effect 
of FATP1 overexpression on steady state levels of these lipid species in the heart and 
plasma using LC-MS/MS. In the heart, there was a modest increase in the level of 
dihydrosphingmyelin  (DHSM) 24:0 in FATP1 mice (Error! Reference source not 
ound.), but there were no differences in other sphingomyelin (SM), AC, or CER species 
(Figure 7, Figure 8, Figure 9). In contrast, there was dramatic remodeling of DG content. 
Very long chain DGs (18:2-22:6, 18:1-22:6, and 18:0-20:4) were increased (+160%, 
+212%, and +56.8%, respectively), while DG 18:2-18:2 and DG 16:0-18:2 were 
modestly decreased (-53.8% and -32.5%, respectively) – leading to a net increase of 
+12% in the DG pool. This was associated with a decrease in expression of genes of DG 
metabolism (HSL, ATGL, DGAT1, and DGAT2) (Figure 10). No differences were 
detected in the plasma levels of CER or SM in FATP1 mice (Figure 11), consistent with 
the lack of systemic effects of cardiac-specific FATP1 overexpression. Thus, increased 
FA uptake into cardiomyocytes due to overexpression of FATP1 is associated with 
remodeling of DG content and composition. 
3.2.2 Increased PKC phosphorylation, decreased AKT phosphorylation, and decreased 
expression of CREB and PGC1α in FATP1 hearts 
 A canonical DG-mediated signaling pathway involves activation of protein kinase 
C (PKC). Preliminary experiments showed that overall PKC activity, as assessed by 
phosphorylation of a common motif in PKC isoforms (α, β, δ, ε, η, and θ) was   
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Figure 3. FATP1 mice have cardiac hypertrophy.  
FATP1 hearts have an increase in absolute wall thickness (AWTd) and posterior wall thickness (PWTd) by 
echocardiography. 	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Figure 4. FATP1 mice have cardiac diastolic dysfunction.  
FATP1 hearts have an increase in end-diastolic diameter (EDD) and early/atrial filling ratio (E/A ratio) by 
echocardiography. 	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Figure 5. Isolated FATP1 hearts have severe diastolic dysfunction.  
FATP1 hearts have an increase in end-diastolic pressure (EDP) with no change in developed pressure 
(DevP) by langendorff. 	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Figure 6. Isolated FATP1 hearts have an increase in long-chain diacylglycerols.  
Cardiac DG content by chain length as measured by LC-MS in nanograms relative to heart mass in 
micrograms. n = 4-5. * = p<0.001 vs wild-type, error bars are mean  ± standard error. 
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Figure 7. FATP1 hearts have no change in acylcarnitine content. 
Acylcarnitine species by chain length as measured by LC-MS in nanograms relative to heart mass in 
micrograms. n = 4-5. 
    
AC
14
:0
AC
18
:3
AC
20
:4
AC
22
:6
AC
16
:0
AC
17
:0
AC
18
:0
AC
20
:0
AC
22
:2
AC
22
:0
0.000
0.001
0.002
0.003
ng
 / 
µ
g
	  	  
27 
 
Figure 8. FATP1 hearts have no change in ceramide content. 
Ceramide species by chain length as measured by LC-MS in nanograms relative to heart mass in 
micrograms. n = 4-5. 
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Figure 9. FATP1 hearts have no change in sphingomyelin content. 
Sphingomyelin species by chain length as measured by LC-MS in nanograms relative to heart mass in 
micrograms. n = 4-5. 
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Figure 10. FATP1 hearts have a decrease in lipid metabolism genes. 
FATP1 hearts have decreased cardiac expression of genes regulating TAG synthesis (DGAT1, DGAT2), 
and DG metabolism (ATGL, HSL) (n = 5-6, error bars are mean ± standard error). 
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Figure 11. FATP1 mice have no change in plasma ceramide or sphingomyelin content. 
Ceramide and sphingomyelin species by chain length as measured by LC-MS in nanograms relative to 
heart mass in micrograms. n = 4-5. 
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increased (+381%) in FATP1 heart (Figure 12). Specifically, phosphorylation of the 
classical isoform PKCα and the novel isoform PKCδ was increased (by 31% and 
245%), but phosphorylation of another novel isoform, PKCε was unchanged (Figure 
13). We next examined potential consequences of increased PKC activity. AKT 
activation (by phosphorylation) was decreased by 25% (Figure 14) and expression of the 
transcription factor cAMP-responsive element binding protein (CREB) was decreased at 
both the transcript (-50%) (Figure 15) and protein (-50%) level (Figure 16). CREB is a 
direct transcriptional activator of the mitochondrial master regulator PGC1α(Herzig	  et	  al.,	  2001), and in association with its decrease, PGC1α transcript was also decreased (-
46%) (Figure 17). Thus, in FATP1 hearts, increased PKC activity is associated with 
inhibition of AKT, down-regulation of CREB, and decreased expression of PGC1α. 
3.2.3 FATP1 hearts have decreased PPARα and mitochondrial fusion gene expression 
PGC1α is known to regulate PPARα expression (Vega,	   Huss,	   &	   Kelly,	   2000), 
which was decreased by 50% in FATP1 hearts (Figure 18). The PPARα/PGC1α axis 
induces transcription of fatty acid oxidation genes and upregulates mitochondrial 
biogenesis and oxidative capacity (Huss,	   Kopp,	   &	   Kelly,	   2002;	   Huss,	   Torra,	   Staels,	  Giguère,	  &	  Kelly,	  2004;	  Lehman	  et	  al.,	  2000). Likewise, the transcript levels for several 
PPAR-dependent FA oxidation enzymes were decreased (Table 1). In addition to 
regulation of mitochondrial metabolism, PGC1α mediates the transcription of genes 
governing mitochondrial fusion (MFN1 and MFN2) (Martin	   et	   al.,	   2014) to regulate 
mitochondrial size. FATP1 hearts exhibited decreased transcript levels of all three  
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Figure 12. FATP1 hearts have increased PKC phosphorylation. 
FATP1 hearts have increased phophorylation of the hydrophobic motif of PKC using a phospho-PKC pan 
(pan PKC isoform antibody; α, β, δ, ε, η, θ) (beta-II S660) antibody (n = 7-9, error bars are mean ± standard 
error). 
    
WT FATP1
0
1
2
3
4
5
pP
K
C
(p
an
) /
 G
A
PD
H *
p-­‐PKC	  (pan) 
GAPDH 	  	  
WT FATP1 
	  	  
33 
 
 
Figure 13. FATP1 hearts have increased phosphorylation of PKC α and PKC δ, but no change in 
PKC ε. 
Expression of phospho-PKCα, phospho-PKCδ, and phospho-PKCε normalized to total PKCα, PKCδ, and 
PKCε, respectively. n = 7-9. * = p<0.05 vs wild-type, error bars are mean  ± standard error.    
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Figure 14. FATP1 hearts have decreased AKT phosphorylation. 
Phosphorylated AKT relative to total AKT expression normalized to GAPDH. n = 7-9. * = p<0.05 vs wild-
type, error bars are mean  ± standard error.  
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Figure 15. FATP1 hearts have decreased CREB transcript. 
Transcript level of cAMP-responsive element binding protein (CREB) normalized to GAPDH. n = 7-9. * = 
p<0.05 vs wild-type, error bars are mean  ± standard error.  
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Figure 16. FATP1 hearts have decreased CREB protein expression. 
CREB protein expression normalized to GAPDH. n = 7-9. * = p<0.05 vs wild-type, error bars are mean  ± 
standard error.  
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Figure 17. FATP1 hearts have decreased PGC1α transcript. 
PGC1α transcript normalized to GAPDH. n = 7-9. * = p<0.05 vs wild-type, error bars are mean  ± standard 
error.  
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Figure 18. FATP1 hearts have decreased PPARα, MFN1, MFN2, and OPA1 transcript. 
Transcript level of PPAR α., MFN1, MFN2, and OPA1 normalized to GAPDH. n = 7-9. * = p<0.05 vs 
wild-type, error bars are mean  ± standard error.  
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Table 1: Transcript fold change of PPAR target genes by PCR array. N=2 
    
Gene Name Gene Symbol Fold Change Gene Name! Gene Symbol Fold Change!
Acaa2 NM_177470 0.22 Mlycd! NM_019966 0.52!
Acadl NM_007381 0.46 Mmp9! NM_013599 0.79!
Acadm NM_007382 0.52 Ncoa3! NM_008679 0.47!
Acox1 NM_015729 0.53 Ncoa6! NM_019825 0.67!
Acox3 NM_030721 0.72 Nr1h3! NM_013839 0.43!
Acsl1 NM_007981 0.52 Olr1! NM_138648 1.30!
Acsl3 NM_001033606 0.71 Pck1! NM_011044 0.41!
Acsl4 NM_019477 0.98 Pck2! NM_028994 1.89!
Acsl5 NM_027976 1.03 Pdpk1! NM_011062 0.90!
Adipoq NM_009605 0.54 Pltp! NM_011125 0.66!
Angptl4 NM_020581 0.98 Ppara! NM_011144 0.40!
Apoa1 NM_009692 0.23 Ppard! NM_011145 0.65!
Apoe NM_009696 1.14 Pparg! NM_011146 0.53!
BC006779 NM_183162 0.42 Ppargc1a! NM_008904 0.78!
Cd36 NM_007643 0.67 Ppargc1b! NM_133249 0.77!
Chd9 NM_177224 0.76 Pprc1! NM_001081214 0.58!
Clu NM_013492 0.52 Pten! NM_008960 0.73!
Cpt1a NM_013495 1.04 Rxra! NM_011305 0.70!
Cpt1b NM_009948 0.57 Rxrb! NM_011306 0.94!
Cpt2 NM_009949 0.38 Rxrg! NM_009107 0.55!
Creb1 NM_133828 0.76 Scd1! NM_009127 0.93!
Crebbp NM_001025432 0.65 Sirt1! NM_019812 0.61!
Cyp27a1 NM_024264 1.10 Slc22a5! NM_011396 0.61!
Cyp4a10 NM_010011 0.41 Slc27a1! NM_011977 34.17!
Dgat1 NM_010046 0.48 Slc27a4! NM_011989 0.80!
Ehhadh NM_023737 0.36 Slc27a5! NM_009512 0.28!
Eln NM_007925 0.78 Slc27a6! NM_001081072 2.22!
Ep300 NM_177821 0.68 Smarcd3! NM_025891 0.71!
Etfdh NM_025794 0.51 Sorbs1! NM_009166 0.58!
Fabp1 NM_017399 0.43 Src! NM_009271 1.07!
Fabp3 NM_010174 0.53 Tgs1! NM_054089 0.81!
Fabp4 NM_024406 0.63 Txnip! NM_023719 0.98!
Fabp5 NM_010634 1.02 Ucp1! NM_009463 0.85!
Fabp7 NM_021272 0.74 Actb! NM_007393 1.23!
Fads2 NM_019699 0.58 B2m! NM_009735 1.00!
Fgr NM_010208 2.38 Gapdh! NM_008084 1.03!
Gyk NM_008194 1.20 Gusb! NM_010368 0.88!
Hif1a NM_010431 1.73 Hsp90ab1! NM_008302 0.90!
Hmgcs2 NM_008256 0.42 
Hspd1 NM_010477 1.00 
Ilk NM_010562 0.82 
Klf10 NM_013692 0.86 
Lpl NM_008509 0.40 
Med1 NM_013634 0.77 
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mitochondrial fusion genes, mitofusin 1 (MFN1, -50%), mitofusin 2 (MFN2, -28%), and 
optic atrophy 1 (OPA1, -42%) (Figure 18), that was associated with decreased protein 
expression (-58%, -33%, and -50%, respectively, Figure 19). There was no change in the 
transcript for the fission regulator DRP1 (data not shown). These alterations in the 
transcriptional profile of FATP1 hearts suggest a decrease in mitochondrial fusion. 
3.2.4 Increased lipid accumulation and altered mitochondrial morphology in FATP1 
hearts 
 Electron micrographs (EMs) were examined to determine the effect of 
FATP1 overexpression on subcellular lipid accumulation and mitochondrial morphology 
(Figure 20). FATP1 hearts showed an 8-fold increase in lipid droplet count (Figure 21), 
in agreement with previously published studies showing increased lipid uptake with 
FATP1 overexpression (Chiu	   et	   al.,	   2005). Analysis of mitochondrial morphology 
showed two distinct populations of mitochondria. Mitochondrial size (median 
mitochondrial area) in the predominant population was decreased by 52% (Figure 22). 
FATP1 hearts also had a second distinct population (approximately 1.6% of total 
mitochondria) of vacuolated mitochondria (Figure 23) with aberrant cristae structure. 
Despite the changes in size, mitochondrial volume density was unchanged in FATP1 
hearts as assessed by EM (Figure 24) and by protein expression of the mitochondrial 
mass marker VDAC1 (Figure 25).  
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Figure 19. FATP1 hearts have decreased MFN1, MFN2, and OPA1 protein expression. 
Protein expression of MFN1, MFN2, and OPA1 normalized to GAPDH. n = 7-9. * = p<0.05 vs wild-type, 
error bars are mean  ± standard error.  
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Figure 20. FATP1 hearts have altered mitochondrial morphology on electron micrographs. 
Representative electron micrographs from WT and FATP1 hearts with mitochondria (M), sarcomeres (S), 
and lipid droplets (L) labeled.  
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Figure 21. FATP1 hearts have increased lipid droplets on electron micrographs. 
Lipid droplet count quantified as lipid droplets divided by total grid intersections counted after elimination 
of blank space and nucleus. Each replicate was compiled from the mean of three EM images from one heart 
(n = 4, * = p<0.05 vs wild-type, error bars are mean ± standard error).  
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Figure 22. FATP1 hearts have increased decreased mitochondrial size on electron micrographs. 
Mitochondrial size (median area) was quantified by free-hand tracing in four standard quadrants per image. 
Each replicate was compiled from the mean of three EM images from one heart (n = 4, * = p<0.05 vs wild-
type, error bars are mean ± standard error).  
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Figure 23. FATP1 hearts have increased debris accumulation on electron micrographs. 
Vacuolated mitochondrial count quantified by grid intersections containing vacuolated mitochondria 
relative to total counted mitochondria grid points and representative image. Each replicate was compiled 
from the mean of three EM images from one heart (n = 4, * = p<0.05 vs wild-type, error bars are mean ± 
standard error).  
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Figure 24. FATP1 hearts have unchanged mitochondrial volume density on electron micrographs. 
Mitochondria volume density was as quantified on electron micrograph relative to total counted grid points. 
Each replicate was compiled from the mean of three EM images from one heart (n = 4, error bars are mean 
± standard error).  
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Figure 25. FATP1 hearts have unchanged mitochondrial mass by immunoblot. 
Mitochondrial mass quantified by immunoblot density of the outer mitochondrial membrane marker 
VDAC1 relative to the loading control GAPDH. n = 4, error bars are mean ± standard error).  
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3.2.5 Complex II-driven oxygen consumption is decreased in FATP1 cardiac 
mitochondria with preserved ATP production 
Coincident with the changes in mitochondrial morphology and PGC1α 
expression, respiration was decreased in mitochondria isolated from FATP1 hearts. 
Complex I-driven (pyruvate + malate) ADP-stimulated (state III) oxygen consumption 
was unchanged (Figure 26). However, complex II-driven (succinate + rotenone) state III 
respiration was decreased by 33% in FATP1 mitochondria, and this decrease persisted 
after FCCP-induced uncoupling (-26%). Interestingly, there was a 57% decrease in 
complex-II driven oligomycin-inhibited respiration (state IV) (Figure 27), leading to a 
54% increase in the respiratory control ratio (state III/state IV; data not shown) indicative 
of a decrease in proton leak and increased mitochondrial efficiency. 
 Decreased complex II-driven oxygen consumption may be due to impaired ATP 
production and/or increased efficiency of ATP production per mole of oxygen consumed. 
Measurement of the maximal rate of ATP synthesis from isolated mitochondria showed 
that FATP1 overexpression did not affect the rate of maximal ATP synthesis with 
complex I or complex II substrates (Figure 28). Thus, FATP1 overexpression leads to a 
decrease in complex II-driven respiration, but preserved capacity to generate ATP 
suggestive of an increase in ATP synthesis efficiency. 
3.2.6 FATP1 hearts have decreased mitochondrial complex II transcript, protein, and 
activity 
 To delineate the mechanism of decreased maximal complex II mitochondrial 
respiration in FATP1 hearts, complex II expression and activity were measured. Complex  
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Figure 26. Mitochondria from FATP1 hearts exhibit unchanged complex I-driven oxygen 
consumption. 
Oxygen consumption rate (OCR) in picomoles of oxygen per minute per microgram of isolated 
mitochondria. A. Complex I substrate = pyruvate and malate. (n = 6-8. N.S. = not significant. Error bars are 
mean ± standard error).  
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Figure 27. Mitochondria from FATP1 hearts exhibit decreased complex II-driven oxygen 
consumption. 
Oxygen consumption rate (OCR) in picomoles of oxygen per minute per microgram of isolated 
mitochondria. Complex II substrate = succinate and rotenone. (n = 6-8. * = p<0.05 vs wild-type. Error bars 
are mean ± standard error).  
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Figure 28. Mitochondria from FATP1 hearts exhibit unchanged ATP synthesis rates. 
ATP synthesis rate as picomoles of ATP per minute per microgram of isolated mitochondria. Complex I 
substrate = pyruvate and malate. Complex II substrate = succinate and rotenone. (n = 4. N.S. = not 
significant. Error bars are mean ± standard error).  
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II subunit B (SDHB) transcript was decreased by 60% (Figure 29) and protein expression 
was decreased by 31% (Figure 30). Likewise, complex II activity as measured by the 
production of ubiquinol by the isolated complex was decreased by 62% (Figure 31). 
Thus, FATP1 overexpression causes downregulation of complex II expression resulting 
in decreased complex II-driven maximal respiration. 
3.2.7 ROS production is unchanged from FATP1 cardiac mitochondria and lack of 
protective effect of catalase overexpression in FATP1 mice 
Cardiac mitochondrial ROS production is increased in models of obesity in which 
FA oxidation is increased (Boudina	  &	  Abel,	  2007). In mice with diet-induced obesity, 
we found that the rate of cardiac mitochondrial H2O2 production is increased in 
association with mitochondrial dysfunction (Sverdlov	   et	   al.,	   2014). Contrary to 
expectations, FATP1 mitochondria showed no change in H2O2 production when supplied 
with complex I substrate, and there was a trend towards decreased ROS production with 
complex II substrate (Figure 32) - suggesting that increased FA uptake and decreased 
mitochondrial oxygen consumption in FATP1 hearts is not associated with mitochondrial 
oxidant overproduction. 
Measurement of isolated mitochondrial ROS production may not fully describe 
potential sources or subcellular compartments of FA-mediated cardiomyocyte ROS. To 
further determine whether mitochondrial oxidative damage and/or signaling contribute to 
the development of FATP1-mediated cardiac dysfunction, mice overexpressing the 
antioxidant catalase in the mitochondrial matrix (mCAT) were crossed with FATP1 mice, 
and cardiac structure and function were assessed by echocardiography. Consistent with  
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Figure 29. Mitochondria from FATP1 hearts exhibit a decrease in SDHB transcript. 
Decreased transcript level of the complex II subunit B (SDHB) relative to GAPDH. n= 5. * = p<0.05 vs 
wild-type. Error bars are mean ± standard error).  
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Figure 30. Mitochondria from FATP1 hearts exhibit a decrease in SDHB protein expression. 
Decreased protein expression of the complex II subunit B (SDHB) normalized to VDAC1. n= 5. * = p<0.05 
vs wild-type. Error bars are mean ± standard error).  
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Figure 31. Mitochondria from FATP1 hearts exhibit a decrease in complex II activity. 
Decreased complex II activity, measured as mOD per minute per microgram of protein. n=3-4. * = p<0.05 
vs wild-type. Error bars are mean ± standard error).  
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Figure 32. Mitochondria from FATP1 hearts exhibit unchanged mitochondrial H2O2 production. 
H2O2 production rate measured as picomoles of H2O2 per minute per milligram of isolated mitochondria. (n 
= 4 for H2O2 production. n.s. = not significant. Error bars are mean ± standard error). 
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the lack of increased oxidant production in FATP1 mitochondria, mCAT had no effect on 
cardiac hypertrophy (total wall thickness) (Figure 33) or diastolic function in FATP1 
mice (Em) (Figure 34). These findings suggest that structural remodeling and diastolic 
dysfunction in FATP1 hearts are not mediated by excessive mitochondrial oxidant 
production. 
3.3 Discussion 
An unresolved question is the role of FA excess, per se, in cardiac mitochondrial 
dysfunction in MHD (Boudina	  &	  Abel,	  2007). The FATP1 mouse is a unique model of 
FA-induced cardiomyopathy in which only the cardiomyocyte is exposed to excess FA, 
thereby allowing investigation of the effect of sustained cardiomyocyte lipid 
accumulation on mitochondrial structure and function in the absence of confounding 
systemic factors. This study provides several new findings. First, in FATP1 hearts the 
intracellular lipid pool is altered with a net increase in DG levels. Second, increased DG 
levels are associated with activation of PKC, inhibition of CREB and AKT, and 
decreased expression of the PGC1α/PPARα axis. Third, in FATP1 hearts mitochondrial 
size is decreased in association with down-regulation of MFN1, MFN2, and OPA1. 
Fourth, in FATP1 hearts mitochondrial respiration is decreased but maximal ATP 
production is preserved. Lastly, in FATP1 hearts mitochondrial ROS is not increased, and 
mitochondrial catalase does not ameliorate the cardiac phenotype.   
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Figure 33. FATP1xmCAT mice show no change in cardiac hypertrophy. 
Total wall thickness from FATP x mCAT hearts by echocardiography. (n = 3-5. n.s. = not significant. Error 
bars are mean ± standard error). 
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Figure 34. FATP1xmCAT mice show no change in cardiac diastolic dysfunction. 
Myocardial relaxation velocity (Em) from FATP x mCAT hearts by echocardiography. (n = 3-5. n.s. = not 
significant. Error bars are mean ± standard error). 
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3.3.1 Structural mitochondrial remodeling  
In the FATP1 hearts mitochondrial size is decreased. Lipid excess in other organs 
has been shown to cause mitochondrial fragmentation (Las,	  Serada,	  Wikstrom,	  Twig,	  &	  Shirihai,	   2011;	   Molina	   et	   al.,	   2009). A decrease in mitochondrial size may reflect a 
decrease in fusion due to decreased expression of MFN1, MFN2, and OPA1, all of which 
were markedly reduced at the transcript and protein level in FATP1 hearts. The 
transcription of MFN1 and MFN2 in the heart is regulated in part by PGC1α (Martin	  et	  al.,	   2014;	   Soriano	   et	   al.,	   2006), which was decreased in FATP1 hearts. Additionally, 
OPA1 transcription is promoted by AKT (Din	  et	   al.,	   2013;	  Parra	  et	   al.,	   2014), which 
was inhibited in FATP1 hearts. Taken together, these findings suggest that sustained 
cardiomyocyte FA excess leads to down-regulation of transcriptional regulators of 
mitochondrial fusion. The functional consequences of decreased mitochondrial fusion 
remain to be determined. 
 While downregulation of PGC1α expression is typically associated with a 
decrease in mitochondrial biogenesis, overall mitochondrial mass was unaffected in the 
FATP1 heart –suggesting a decrease in mitochondrial turnover. Lipid excess in the 
pancreatic beta cell decreases mitochondrial turnover by impairing autophagy (Las	  et	  al.,	  2011). Additionally, MFN2, which is decreased in the FATP1 heart, may have a role in 
regulating autophagy (Zhao	   et	   al.,	   2012). It is possible that the appearance of a 
population of large vacuolated mitochondria in FATP1 hearts reflects a block in 
autophagic flux and potentially mitophagy mediated by lipid excess. 
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3.3.2 Functional mitochondrial remodeling 
 Structural remodeling was associated with decreased complex II activity as 
reflected by a decrease in maximal state III oxygen consumption with complex II 
substrates, and was associated with a decrease in the expression of complex II subunit B 
that is mediated, at least in part, by a decrease in transcription. It is likely that decreased 
complex II expression is mediated by the observed decrease in PGC1α, which is known 
to regulate SDHB expression via NRF1 and NRF2 (J.-­‐Q.	  Chen,	  Cammarata,	  Baines,	  &	  Yager,	  2009).   
Surprisingly, decreased complex II state III oxygen consumption was not 
associated with a decrease in maximal complex II-mediated ATP production. This 
dissociation between respiration and ATP production may reflect a decrease in 
mitochondrial proton leak, as suggested by the concomitant decrease in oligomycin-
inhibited state IV respiration. A larger decrease in proton leak, when compared to state III 
respiration, would increase mitochondrial coupling efficiency and thereby help to 
maintain ATP production. The observed increase in coupling efficiency in FATP1 
mitochondria differs from observations in diabetic mice (db/db and ob/ob) in which there 
is decreased coupling efficiency (Boudina	   &	   Abel,	   2006). However, in diabetic mice 
uncoupling is thought to be related to increased mitochondrial ROS, which are not 
increased in FATP1 mitochondria (discussed below). The mitochondrial isolation we 
used selectively enriches sub-sarcolemmal mitochondria, making it possible that impaired 
function of inter-fibrillar mitochondria was missed. However, this is unlikely as sub-
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sarcolemmal mitochondria appear to be more affected in MHD, while inter-fibrillar 
populations are relatively spared (Dabkowski	  et	  al.,	  2010).  
3.3.3 Remodeling of the lipid pool and DG-mediated signaling 
 The major consequence of FATP1 overexpression is increased transport of long 
chain FAs with no change in steady state triglyceride (TG), cholesterol ester or 
cardiolipin levels (Chiu	  et	  al.,	  2005). Therefore, quantitative and/or qualitative changes 
in the intracellular lipid pool may play a central role in mediating mitochondrial 
remodeling. FATP1 overexpression had no effect on myocardial content of potentially 
toxic CER or AC species. However, there was a substantial remodeling of the DG pool 
with 2-3 fold increases in some very long chain DG (18:2-22:6, 18:1-22:6, and 18:0-20:4) 
resulting in a 12% increase in net DG content. The myocardial lipid profile in FATP1 
mice appears to be less toxic than that of the acyl-CoA synthetase (ACS) overexpressing 
mouse (Chiu	  et	  al.,	  2001) in which accumulation of DG, TG and CER is associated with 
a more severe cardiac phenotype with systolic dysfunction and increased mortality.  
DG is a major regulator of PKC, which was activated in FATP1 hearts and 
associated with decreases in CREB expression, AKT phosphorylation and PGC1α 
expression. Activation of PKC can induce mitochondrial fragmentation and dysfunction (Nowak,	  Bakajsova,	  &	  Samarel,	  2011;	  Patergnani	  et	  al.,	  2013), possibly via inhibition 
of AKT (Motley	   et	   al.,	   2001) and/or CREB (Drosatos	   et	   al.,	   2011;	   Mehta,	   2014). 
CREB is a direct transcriptional activator of PGC1α (Herzig	   et	   al.,	   2001), and AKT 
regulates mitochondrial biogenesis via activation of the CREB-PGC1α axis (Y.	  Li	  et	  al.,	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2013). Thus, increased DG provides a plausible mechanism by which PGC1α is down-
regulated in FATP1 hearts.  
The coordinated down-regulation of PPARα and PGC1α in FATP1 hearts that we 
observed is somewhat surprising because PPARα promotes lipid utilization (Scarpulla,	  2008), which is increased in the FATP1 heart (Chiu	   et	   al.,	   2005). In contrast to the 
FATP1 mouse, in diabetic ob/ob and db/db mice the changes in cardiac PPARα and 
PGC1α are discordant, with increased PPARα and decreased PGC1α expression. This is 
associated with decreased mitochondrial function (as in the FATP1 heart) but also with 
increased ROS production, increased uncoupling, and impaired cardiac function (Boudina	   et	   al.,	   2005;	   Dabkowski	   et	   al.,	   2010). Likewise, cardiomyocyte 
overexpression of PPARα has pathologic consequences (Finck	  et	  al.,	  2003), and mimics 
the diabetic phenotype (Aubert,	   Vega,	   &	   Kelly,	   2013;	   Duncan,	   2011). Since in the 
FATP1 heart ATP production was preserved, it appears that the coordinated decrease in 
PPARα and PGC1α in the FATP1 heart leads to mitochondrial remodeling that is of 
benefit in the setting of nutrient excess.  
3.3.4 Role of mitochondrial ROS 
Mitochondrial ROS are increased in other models of MHD (Boudina	   &	   Abel,	  2007;	   Sverdlov	   et	   al.,	   2014) and overexpression of antioxidants can ameliorate 
pathologic cardiac remodeling in diabetic mice (Cai	   et	   al.,	   2006;	   Liang	   et	   al.,	   2002;	  Shen,	   Zheng,	  Metreveli,	   &	   Epstein,	   2006;	   Ye	   et	   al.,	   2004) and protect mitochondrial 
structure and function (Dai	   &	   Rabinovitch,	   2011;	   Dai	   et	   al.,	   2012). Surprisingly, 
mitochondrial H2O2 production was not increased in FATP1 hearts. Furthermore, 
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transgenic overexpression of mitochondrial-targeted catalase, which attenuates cardiac 
oxidative stress in other models (Dai	  et	  al.,	  2009;	  Schriner	  et	  al.,	  2005), did not exert a 
beneficial effect on the cardiac phenotype in FATP1 mice. Thus, ROS do not appear to 
play a role in mediating the cardiac phenotype in FATP1 mice. 
3.3.5 Conclusion 
 Overexpression of FATP1 in the heart leads to DG accumulation, altered 
intracellular signaling, coordinated down-regulation of PPARα/PGC1α, and both 
structural and functional mitochondrial remodeling (Figure 35). There are several 
noteworthy divergences from other models of MHD related to diabetes or altered lipid 
metabolism. In particular, mitochondrial remodeling in response to cardiac myocyte-
specific FA excess, per se, leads to compensated function with sustained ability to 
generate ATP in the absence of pathologic ROS production. These findings suggest that 
systemic factors beyond those related to increased FA levels play an important role in 
mediating the impaired mitochondrial function in MHD.  
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Figure 35. Model of effect of FATP1 overexpression on mitochondrial structure and function.  
FATP1 overexpression in the cardiomyocyte leads to fatty acid (FA) excess, which causes diacylglycerol 
(DG) accumulation and protein kinase C activation (pPKC), which inhibits CREB and AKT and leads to 
decreased expression of PGC1α, MFN1, MFN2 and OPA1 to decrease mitochondrial size and respiration. 
 
 
	  	  
66 
Chapter 4: High Fat High Sucrose Diet Increases Mitochondrial Oxidant 
Generation to Cause Mitochondrial Dysfunction and Cardiac Remodeling 
4.1  Rationale 
Obesity leads to metabolic heart disease (MHD) characterized by oxidative stress, 
impaired energetics, and myocardial structural and functional remodeling through an 
unknown mechanism. Mitochondria are responsible for producing large amounts of ATP 
to maintain cardiac function, and mitochondrial dysfunction can result in an energetic 
deficit accompanied by an increase in generation of reactive oxygen species (ROS). 
Increased ROS production leads to oxidative stress via oxidative post-translational 
modification (OPTM) of proteins with consequent pathologic changes in intracellular 
protein activity. While cardiac oxidative stress is known to increase in association with 
MHD, it is unknown if 1) mitochondria are a source of ROS, 2) mitochondrial 
dysfunction is driven by OPTM of mitochondrial proteins, and 3) attenuation of 
mitochondrial ROS production can prevent pathologic cardiac remodeling. 
The Colucci lab previously showed that mice fed a high fat high sucrose (HFHS) 
diet develop MHD, which is associated with an increase in oxidative stress in the heart 
and attenuated by co-administration of a polyphenol compound (Qin et al., 2012). 
Additionally, HFHS diet leads to OPTM of mitochondrial proteins in the heart, 
suggestive of an increased oxidant burden in the mitochondria (Behring et al., 2014). In 
chapter three, I found that lipid excess in the cardiomyocyte leads to a decrease in 
mitochondrial biogenesis, with consequences on mitochondrial structure and function. 
Thus, in this study, I hypothesized that HFHS diet leads to mitochondrial dysfunction in 
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the heart via increased mitochondrial ROS and/or lipid-driven transcriptional remodeling 
with a causative role in cardiac remodeling. To determine the effect of mitochondrial 
ROS in MHD, I utilized mice with targeted overexpression of the antioxidant enzyme 
catalase in mitochondria (mCAT). These mice are known to have a decrease in 
mitochondrial ROS production, and prevent cardiac oxidative stress in association with 
cardiac aging and pressure overload. 
4.2 Experiments 
4.2.1 HFHS diet increases cardiac mitochondrial ROS production 
Mitochondria isolated from hearts of mice fed HFHS diet for 4 months had an 
increase in the rate of H2O2 production when provided with substrates to complex I 
(pyruvate and malate) or complex II (succinate and rotenone), (+323.3% and +31.1%) 
(Figure 36). 
4.2.2 HFHS diet impairs mitochondrial function in the heart 
To determine the effect of HFHS diet on cardiac mitochondrial function, rates of 
mitochondrial oxygen consumption and ATP synthesis were assessed. HFHS 
mitochondria had a 27.4% decrease in maximal ADP-stimulated oxygen consumption 
(state III) with complex II substrate (succinate, with rotenone). Similarly, oligomycin-
inhibited (state IV) oxygen consumption was decreased, as was FCCP-uncoupled oxygen 
consumption (Figure 37). Complex I-driven respiration, on the other hand, was 
unchanged (Figure 38). In agreement with the decrease in mitochondrial oxygen 
consumption, the rate of ATP synthesis was decreased in HFHS   
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Figure 36. Hearts of HFHS-fed mice have an increase in mitochondrial H2O2 production. 
Mitochondrial H2O2 production rate shown as nanomol/min/mg of mitochondrial protein with pyruvate and 
malate (complex I substrate) and succinate and rotenone (complex II substrate). n = 12. * = p<0.05 vs wild-
type, error bars are mean  ± standard error.  
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Figure 37. Hearts of HFHS-fed mice have a decrease in mitochondrial oxygen consumption with 
complex II substrate. 
Mitochondrial oxygen consumption rate shown as picomol/min with succinate and rotenone (complex II 
substrate). n = 8. * = p<0.05 vs wild-type, error bars are mean  ± standard error.  
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Figure 38. Mitochondria from HFHS-fed mice have unchanged oxygen consumption with complex I 
substrates. 
Mitochondrial oxygen consumption rate shown as picomol/min with pyruvate and malate (complex I 
substrate). n = 4. ns = not significant, error bars are mean  ± standard error.  
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mitochondria with substrates to complex I (-12.6%) and complex II (-16.2%) (Figure 39). 
Finally, 1 month of HFHS diet was enough to cause a decrease in complex II-driven state 
III oxygen consumption (Figure 40), suggesting an early and persistent pattern of 
mitochondrial dysfunction with HFHS diet. 
4.2.3 HFHS-induced mitochondrial dysfunction is affected by mouse housing conditions 
During the course of studying the effect of HFHS diet on cardiac mitochondrial 
function, mouse housing was changed from a small room with micro filter top (MFT) 
cages to a large room with individually ventilated cages (IVC) as part of a renovation of 
the Boston University animal facilities. It became apparent that animals fed HFHS diet 
for 1 month in IVC did not develop HFHS-induced decreases in mitochondrial oxygen 
consumption (Figure 41) or ATP synthesis (Figure 42) relative to littermates in MFT 
cages. 
4.2.4 HFHS diet leads to a decrease in cardiac mitochondrial complex II activity  
To understand the potential mechanisms underlying HFHS-induced mitochondrial 
dysfunction, the activity of isolated complexes in the electron transport chain (ETC) was 
measured from hearts of mice after 4 months of HFHS diet. The activity of complex II 
(succinate dehydrogenase, SDH), measured as the rate of conversion of ubiquinone to 
ubiquinol, was decreased (-60%) in HFHS mitochondria (Figure 43). 
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Figure 39. Mitochondria from HFHS-fed mice have decreased ATP production. 
Mitochondrial ATP production rate shown as pmol/min with pyruvate and malate (complex I) and 
succinate and rotenone (complex II). n = 8. * = p<0.05, error bars are mean  ± standard error. 
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Figure 40. Mitochondria from mice fed HFHS for 1 month have decreased oxygen consumption. 
Mitochondrial oxtgen consumption rate shown as picomol/min with succinate and rotenone (complex II 
substrate). n = 4. * = p<0.05, error bars are mean  ± standard error. 
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Figure 41. Mice in IVC do not develop HFHS-induced decrease in oxygen consumption. 
Oxygen consumption rate using succinate and rotenone in littermates housed under different conditions. 
n=1.   
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Figure 42. Mice in IVC do not develop HFHS-induced decrease in ATP synthesis. 
ATP synthesis rate using succinate and rotenone in littermates housed under different conditions. n=1.   
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Figure 43. Hearts of HFHS-fed mice have a decrease in complex II activity. 
Rate of production of ubiquinol as a measure of complex II activity. n = 4. *** = p<0.0001 vs wild-type, 
error bars are mean  ± standard error.  
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4.2.5 HFHS-fed mice have unchanged cardiac mitochondrial biogenesis, structure, and 
protein expression 
Mitochondrial structure and function can be regulated at the transcriptional level by 
PGC1α. I examined PGC1α transcript in hearts after HFHS diet, and found it to be 
increased at 1 month of diet (+28.1%), but unchanged at 4 and 8 months of diet (Figure 
44). This was associated with an increase in expression of three downstream genes 
regulating mitochondrial fusion, MFN1, MFN2, and OPA1 at 1 month of diet (+11.2%, 
+20.4%, +34.8%, respectively) (Figure 45). Preliminary results suggest that this may be 
associated with a slight increase in mitochondrial size on electron micrographs (Figure 
46, Figure 47), with no change in mitochondrial volume density (Figure 48). Finally, 
there was no change in expression of representative protein subunits in complexes I, II, 
III, IV, and V (Figure 49). 
4.2.6 HFHS-induced cardiac mitochondrial dysfunction is partially corrected in 
reducing environment in vitro 
We previously showed that HFHS diet leads to OPTM of mitochondrial proteins 
(Behring et al., 2014). To determine if oxidative stress plays a role in HFHS-induced 
mitochondrial dysfunction, mitochondrial ATP synthesis and complex activity were 
measured after co-incubation of isolated mitochondrial with the reducing agent 
dithiothreitol (DTT) to remove all reversible cysteine oxidations. DTT treatment led to a 
restoration of the ATP synthesis rate with complex II substrates (Figure 50), but not with 
complex I substrates (Figure 51). Similarly, complex II activity in HFHS mitochondria 
was restored to CD levels with DTT (Figure 52), suggesting a role of 
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Figure 44. Hearts of HFHS-fed mice have an early increase in PGC1α transcript. 
PGC1α transcript level normalized to GAPDH and relative to CD. n = 4. * = p<0.05 vs wild-type, error 
bars are mean  ± standard error.  
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Figure 45. Hearts of HFHS-fed mice have an early increase in fusion gene transcript. 
Transcript levels of MFN1, MFN2, and OPA1 normalized to GAPDH and relative to CD. n = 4. * = p<0.05 
vs wild-type, error bars are mean  ± standard error.  
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Figure 46. Hearts of HFHS-fed mice by electron micrographs. 
Representative image. n=1.  
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Figure 47. Hearts of HFHS-fed mice may have slightly increased mitochondrial size. 
Mitochondrial size as measured on electron micrographs. N=1.  
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Figure 48. Hearts of HFHS-fed mice may have unchanged mitochondrial density. 
Mitochondrial density as measured on electron micrographs. N=1.  
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Figure 49. Hearts of HFHS-fed mice have unchanged complex protein expression. 
Protein expression of ETC subunits from complex I, complex II, complex III, complex IV, and complex V 
all normalized to VDAC1. N=4. 
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Figure 50. Decreased complex II-driven ATP synthesis in HFHS mitochondria is correctable in 
reducing conditions. 
ATP synthesis rate using succinate and rotenone in CD and HFHS mitochondria in the presence or absence 
of DTT. N=4-6. NS = Not significant, * = p<0.05.  
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Figure 51. Decreased complex I-driven ATP synthesis in HFHS mitochondria is not correctable in 
reducing conditions. 
ATP synthesis rate using pyruvate and malate in CD and HFHS mitochondria in the presence or absence of 
DTT. N=4-6. NS = Not significant. 
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Figure 52. Decreased complex II activity in HFHS mitochondria is correctable in reducing 
conditions. 
Complex II activity in CD and HFHS mitochondria in the presence or absence of DTT. N=4. *** = 
P<0.0001 vs WT CD. ### = P<0.0001 vs WT HFHS.  
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reversible cysteine OPTM in HFHS-induced mitochondrial dysfunction. 
4.2.7 Overexpression of catalase in mitochondria prevents HFHS-induced cardiac 
mitochondrial dysfunction 
Overexpression of the antioxidant enzyme catalase in mitochondria (mCAT) can 
prevent mitochondrial oxidative stress in the heart. To determine if HFHS-induced 
mitochondrial oxidative stress mediates mitochondrial dysfunction, we examined if 
mCAT mice have less mitochondrial impairment than wild-type littermates after HFHS 
feeding. Indeed, mitochondrial H2O2 production was eliminated in mCAT hearts with 
complex I (Figure 53) and complex II (Figure 54) substrates, and the rates of 
mitochondrial ATP synthesis (Figure 55, Figure 56) and oxygen consumption (Figure 57) 
in mCAT hearts were unperturbed by HFHS diet. Finally, oxidative modifications of 
complex II subunit B (SDHB), as assessed by a biotin switch assay, were increased in 
HFHS-fed hearts and prevented in mCAT hearts (Figure 58). 
4.2.8 Overexpression of mitochondrial catalase prevents HFHS-induced cardiac 
remodeling 
We previously showed that HFHS diet leads to cardiac hypertrophy and impaired 
cardiac relaxation. ROS is a known mediator of cardiac hypertrophy, but the role of 
mitochondrial ROS in the development of HFHS-induced cardiac hypertrophy is 
unknown. Thus, we assessed cardiac wall thickness by echocardiography in mice fed 
HFHS diet for 4 months, and found it to be increased in WT mice fed HFHS relative to 
CD, but unchanged in mCAT mice (Figure 59). Similarly, myocardial relaxation velocity  
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Figure 53. mCAT prevents HFHS-induced complex I-driven H2O2 production. 
H2O2 production rate with pyruvate and malate in WT mice and mCAT littermates fed CD and HFHS diet. 
N=4-6. ** = p<0.001 vs WT CD. ## = p<0.001 vs WT HFHS.  
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Figure 54. mCAT prevents HFHS-induced complex II-driven H2O2 production. 
H2O2 production rate with succinate and rotenone in WT mice and mCAT littermates fed CD and HFHS 
diet. N=4-6. *** = p<0.0005 vs WT CD. ### = p<0.0005 vs WT HFHS.  
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Figure 55. mCAT prevents HFHS-induced complex I-driven decrease in ATP synthesis. 
ATP synthesis rate with pyruvate and malate in WT mice and mCAT littermates fed CD and HFHS diet. 
N=4-6. *** = p<0.0005 vs WT CD. ## = p<0.001 vs WT HFHS.  
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Figure 56. mCAT prevents HFHS-induced complex II-driven decrease in ATP synthesis. 
ATP synthesis rate with succinate and rotenone in WT mice and mCAT littermates fed CD and HFHS diet. 
N=4-6. *** = p<0.0005 vs WT CD. ## = p<0.001 vs WT HFHS.  
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Figure 57. mCAT prevents HFHS-induced complex II-driven decrease in oxygen consumption. 
Maximal ADP-stimulated (State III) oxygen consumption rate with succinate and rotenone in WT mice and 
mCAT littermates fed CD and HFHS diet. N=4. ** = p<0.01 vs WT CD. # = p<0.05 vs WT HFHS.  
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Figure 58. mCAT prevents HFHS-induced oxidative modifications of complex II subunit B. 
Reversible oxidations of SDHB measured by biotin switch assay in WT mice and mCAT littermates fed 
CD and HFHS diet. N=4. *** = p<0.0001 vs WT CD. ### = p<0.0001 vs WT HFHS.   
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Figure 59. mCAT prevents HFHS-induced increase in cardiac total wall thickness. 
Total left-ventricular wall thickness by echocardiography as a measure of cardiac hypertrophy in WT mice 
and mCAT littermates fed CD and HFHS diet. N=4-6. ** = p<0.01 vs WT CD. # = p<0.05 vs WT HFHS.   
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 (Em), an echocardiographic index of cardiac diastolic function, was decreased in WT 
mice fed HFHS diet, but unchanged in mCAT mice after similar feeding (Figure 60). 
4.3 Discussion 
In chapter 3, I found that lipid excess in the heart driven by FATP1 overexpression 
led to a compensated downregulation of mitochondrial function. This was marked by 
decreases in ADP-stimulated mitochondrial oxygen consumption and complex II activity 
with unchanged rates of ATP synthesis and ROS production. Additionally, lipid excess 
induced morphological changes in mitochondrial cristae density and a decrease in 
mitochondrial size. I argued that these changes were driven by a decrease in expression 
of the mitochondrial master regulator PGC1α, with subsequently decreased expression of 
ETC genes and mitochondrial fusion genes. Finally, I found that MHD in FATP1 mice 
was not corrected by catalase overexpression in mitochondria, which suggested that lipid 
overload-driven cardiac remodeling was not mediated by mitochondrial oxidants. 
In this study, I present several novel findings in regards to the effects of dietary 
fat and sugar excess on mitochondrial structure and function in the heart. First, I report 
that HFHS diet leads to increased mitochondrial ROS production and mitochondrial 
dysfunction marked by decreases in ADP-stimulated oxygen consumption, ATP 
synthesis, and complex II activity. Second, mitochondrial dysfunction is not associated 
with a change in ETC transcript level or protein expression, but is attenuated in vitro in 
reducing environments and prevented in vivo by overexpression of the antioxidant 
enzyme catalase in mitochondria. Finally, I report that cardiac remodeling induced by 
HFHS diet is prevented by mitochondrial catalase overexpression.  
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Figure 60. mCAT prevents HFHS-induced decrease in ventricular relaxation velocity. 
Myocardial relaxation velocity as a measure of diastolic function by echocardiography in WT mice and 
mCAT littermates fed CD and HFHS diet. N=4-6. *** = p<0.0001 vs WT CD. ### = p<0.0001 vs WT 
HFHS.   
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4.3.1 Mitochondria as a source of ROS 
HFHS diet leads to an increase in cardiac mitochondrial H2O2 production. The 
Colucci lab previously reported that HFHS-fed mice exhibit an increase in markers of 
cardiac oxidative stress (Qin et al., 2012), but the source of ROS was unclear. It was also 
reported in that study that co-administration of an antioxidant polyphenol compound 
prevented diet-induced cardiac remodeling through an unclear mechanism. Mice with 
genetically-induced diabetes and obesity (db/db) have increased mitochondrial ROS 
production and cardiac oxidative stress (Boudina et al., 2007). Here, I provide evidence 
to suggest that mitochondria are a source of ROS in the heart in the setting of HFHS 
feeding, and that neutralization of ROS in the mitochondria via overexpression of 
catalase prevents diet-induced cardiac remodeling. Since HFHS diet also leads to 
oxidant-mediated mitochondrial dysfunction, these findings suggest that mitochondria act 
as both a source and target of ROS in HFHS-induced MHD. 
4.3.2 Mitochondria as a target of ROS 
HFHS diet leads to a decrease in maximal rates of mitochondrial oxygen 
consumption and ATP synthesis. Obesity in patients is associated with a decrease in 
myocardial energetics correctable by weight loss (Rider et al., 2013; 2012). In mice, 
genetically-induced obesity (db/db and ob/ob) leads to a decrease in ATP synthesis in the 
heart(Boudina et al., 2007). The Colucci lab, in collaboration with others, showed that 
HFHS diet leads to OPTM of ETC proteins (Behring et al., 2014). However, the 
consequences of HFHS diet on cardiac mitochondrial function were previously unknown. 
Here, I present evidence that HFHS diet leads to sustained decreases in the rates of 
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mitochondrial ATP synthesis and oxygen consumption. Additionally, decreases in 
mitochondrial ATP synthesis appear to be mediated by reversible OPTMs, as suggested 
by the in vitro attenuating effect of co-incubation with the thiol reducing agent DTT, as 
well as the prevention in vivo with mitochondrial catalase overexpression. While the 
reversibly-modified protein targets underlying the decrease in ATP synthesis remain 
unclear, the rescue of complex II activity with DTT suggests that one or more of its 
protein subunits may be a target of HFHS-induced ROS. Further studies will be necessary 
elucidate whether OPTM of specific cysteines in complex II mediate ROS-driven 
mitochondrial dysfunction. 
4.3.3 Roles in cardiac remodeling 
HFHS-induced cardiac hypertrophy and diastolic dysfunction were prevented 
with mCAT overexpression. The Colucci lab previously showed that HFHS leads to 
MHD, and is prevented with co-administration of a polyphenol compound. While such 
compounds have pleiotropic effects, the prevention of oxidative stress suggested an 
antioxidant role. Here, I present evidence that confirms that neutralization of ROS, 
specifically in the mitochondrial compartment, prevents hypertrophy and diastolic 
dysfunction. While the mechanism by which oxidative stress in the mitochondria leads to 
MHD in this model is unclear, recent findings may shed some light. ROS have been 
found to directly activate hypertrophic MAP kinase signaling in the cardiomyocyte 
(Pimentel et al., 2006). It is conceivable that increased delivery of substrates to 
mitochondria leads to overproduction of oxidants and increased cytosolic ROS to cause 
diet-induced pathologic hypertrophy. Diastolic function, which is in large related to 
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cardiomyocyte relaxation, is also oxidant-sensitive. Clearance of cytosolic calcium into 
the endoplasmic/sarcoplasmic reticulum (SR/ER) requires active uptake by the SR/ER 
Ca2+ ATPase (SERCA). Sulfonylation of SERCA by excess ROS decreases its function, 
leading to slower clearance of calcium and prolonged relaxation time. Thus, increased 
ROS from mitochondria may lead to slower cardiomyocyte relaxation to cause diastolic 
dysfunction in HFHS mice. Alternatively, since SERCA function is ATP-dependent, the 
decrease in mitochondrial ATP synthesis in HFHS hearts, which is prevented in mCAT 
mice, may also be playing a role in mediating HFHS-induced diastolic dysfunction. 
Finally, it is worth noting that HFHS is a systemic insult, and that mitochondrial catalase 
overexpression is not cardiac-specific. Thus, the prevention of MHD with mCAT may 
potentially be secondary to ROS effects elsewhere in the body, such as the vasculature. 
4.3.4 Housing effects on mitochondrial dysfunction 
In a rather unexpected finding, HFHS-induced decreases in mitochondrial oxygen 
consumption and ATP synthesis were affected by a change in mouse housing conditions. 
Mice housed in individually-ventilated cages (IVC) in a large room did not develop 
similar mitochondrial dysfunction to those housed in microfilter top cages (MFT). While 
the reason for this difference is unclear, there are a number of possibilities. Room noise 
will affect mouse activity level, thereby introducing an exercise variable in the study, 
which would likely have attenuating effects on diet-induced cardiac dysfunction (Hafstad 
et al., 2013). Additionally, differences in cage filtration can affect humidity level, which 
could change animal hydration status with subsequent effects on food intake, blood 
glucose, and/or insulin resistance. While this finding is preliminary and requires further 
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investigation, it may account for some of the variability in findings of groups with respect 
to the effects of diet on the animal heart. 
4.3.5 Differences from FATP1 overexpression 
There are several noteworthy divergent findings in cardiac mitochondrial 
structure and function in HFHS-fed mice relative to mice with cardiomyocyte-specific 
FATP1 overexpression. As previously discussed, FATP1 mice appear to exhibit 
compensated mitochondrial remodeling, with decreased oxygen consumption but 
maintained ATP synthesis and unchanged ROS production. In that model, the decrease in 
oxygen consumption is likely attributed to a decrease in transcription of ETC genes 
driven by a decrease in PGC1α expression. Unchanged ATP synthesis is likely a 
consequence of increased mitochondrial coupling and decreased proton leak. In contrast, 
HFHS hearts have unchanged, or rather slightly upregulated, mitochondrial biogenesis, 
evidenced by PGC1α transcript, and decreases in both ATP synthesis and oxygen 
consumption with unchanged ETC gene expression and corrected in vitro with DTT. In 
conjunction with the increase in ROS production, this finding suggests that HFHS-
induced mitochondrial dysfunction is oxidant-driven. Furthermore, the prevention of 
HFHS-induced mitochondrial dysfunction and cardiac remodeling with mCAT suggests a 
key role of ROS in the pathology, which is not the case in FATP1 x mCAT mice. Finally, 
morphologic changes in mitochondrial structure in FATP1 hearts, with fragmentation and 
cristae disruption, do not appear to occur with HFHS feeding. 
There are a number of differences between the two models which may explain the 
variation in mitochondrial function. First, and perhaps most notable is the nature of 
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nutrient excess, which in FATP1 hearts is only lipids, and does not have a carbohydrate 
component, and the combination of excess fat and sucrose could have synergistic effects 
to impair mitochondrial function. Second, HFHS insult is systemic, and the difference 
between the models may reflect extra-cardiac effects of diet, such as systemic 
hyperglycemia, insulin resistance, and vascular remodeling. Third, FATP1 
overexpression is constitutive, and thus begins very early in life. As such, specific 
adaptions may occur which would not be seen in the setting of a dietary regimen begun at 
8-10 weeks of age. Finally, mouse strain backgrounds are thought to play a role in 
susceptibility to nutrient-mediated disease. HFHS diet was performed in mice on a 
C57BL/6 background, which is thought to be more sensitive to obesity, whereas the 
FATP1 mouse is on FVB background, which is traditionally considered to be more 
resistant to obesity. Taken together, the findings from these chapters suggest that 
cardiomyocyte lipid accumulation may not fully reflect the effects of diet-induced obesity 
on mitochondrial function, and seems to cause MHD through independent mechanisms. 
 
	  	  
102 
Chapter 5: Loss of ABCB10 in Cardiomyocytes Impairs Cardiac Mitochondrial 
Function and Promotes Diet-Induced Cardiac Remodeling 
5.1  Rationale 
ATP-Binding Cassette B10 (ABCB10) is an ATP-requiring transport protein 
located in the inner mitochondrial membrane where it exports an unknown substrate out 
of mitochondria and protects against oxidative stress. In the heart, we previously showed 
that a 50% decrease in whole-body ABCB10 expression does not affect cardiac function 
at baseline, but leads to impaired mitochondrial respiration and cardiac function after 
ischemic injury in an oxidant-dependent mechanism (Liesa et al., 2011). ABCB10 
expression is also essential for erythropoiesis, and mice lacking ABCB10 are anemic at 
embryonic day 10.5 and die by day 12.5. This lethality of the whole body knockout 
mouse has hindered loss-of-function studies of ABCB10 in the heart. Thus, in this study, 
I generate a cardiomyocyte-specific ABCB10 knockout (CM-ABCB10-/-) mouse to 
elucidate its role in maintaining mitochondrial function and cardiac health. 
The Colucci lab previously found that mice fed a high fat high sucrose (HFHS) 
diet develop metabolic heart disease (MHD), characterized by pathologic cardiac 
remodeling and oxidative stress. Additionally, I showed in chapter 4 that mitochondria 
are a source of ROS in the heart after HFHS feeding, and mitochondrial oxidative stress 
plays a causative role in MHD. However, it is unknown if the protective role of ABCB10 
against acute oxidant exposure in cardiac ischemia/reperfusion extends to oxidative stress 
caused by HFHS feeding. I hypothesized that a cardiomyocyte-specific decrease in 
ABCB10 expression would exacerbate mitochondrial dysfunction and cardiac remodeling 
	  	  
103 
induced by HFHS diet. Determining the role of ABCB10 in protecting against HFHS-
induced mitochondrial dysfunction and cardiac remodeling can provide insight into 
disease-modifying pathways dictating patient susceptibility to MHD and clarify the 
mechanisms of cardiac mitochondrial dysfunction in obesity. 
5.2 Experiments 
5.2.1 Generating cardiomyocyte-specific ABCB10+/- and ABCB10-/- mice 
CM-ABCB10+/- and CM-ABCB10-/- mice were generated using the Cre-Lox 
system. In brief, mice with ABCB10 loxP/+ and ABCB10 loxP/loxP were bred with mice 
expressing the Cre recombinase under a cardiomyocyte-specific alpha-myosin heavy 
chain (α-MHC) promoter. Knockout of the Abcb10 gene was confirmed by transcript 
level from whole heart RNA (-96.3%) (Figure 61). 
5.2.2 CM-specific loss of ABCB10 leads to cardiac mitochondrial dysfunction 
It was previously reported that whole-body heterozygous loss of ABCB10 does 
not affect mitochondrial respiration at baseline. I examined the effect of CM-specific 
homozygous loss of ABCB10 on rates of mitochondrial oxygen consumption, ATP 
synthesis and H2O2 production. I observed that at 4 months of age, the rate of maximal 
ADP-stimulated oxygen consumption (state III) with complex I substrates (pyruvate and 
malate) was decreased (Figure 62), while complex II-driven (succinate, with rotenone) 
oxygen consumption was unchanged (Figure 63). Interestingly, state IV oxygen 
consumption, a measure of proton leak, was also decreased, and the rate of ATP synthesis 
was unchanged in mitochondria from CM-ABCB10-/- hearts (Figure 64).   
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Figure 61. Hearts of CM-Abcb10-/- mice have decreased Abcb10 transcript. 
Abcb10 transcript as measured by RT-PCR. N=3, ** = p<0.001. 
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Figure 62. CM-ABCB10-/- hearts have decreased complex I-driven oxygen consumption. 
Mitochondrial oxygen consumption rate with pyruvate and malate. N=5. *p<0.05. 
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Figure 63. CM-ABCB10-/- hearts have unchanged complex II-driven oxygen consumption. 
Mitochondrial oxygen consumption rate with succinate and rotenone. N=5. *p<0.05. 
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Figure 64. CM-ABCB10-/- hearts have unchanged ATP synthesis. 
Mitochondrial ATP synthesis rate with complex I (pyruvate and malate) and complex II  (succinate with 
rotenone) substrates. N=6. 
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This was not associated with a change in mitochondrial biogenesis or fusion gene 
expression (Figure 65). 
5.2.3 CM-specific loss of ABCB10 increases mitochondrial ROS production without 
altering antioxidant gene expression 
As I showed in chapter 4, mitochondrial dysfunction is often associated with, and 
in some cases is driven by a pathological increase in mitochondrial ROS production or 
decrease in antioxidant capacity. The rate of mitochondrial H2O2 production was 
examined from hearts of CM-ABCB10-/- mice, and was found to be increased with 
complex I substrates, and trended towards an increase with complex II substrate (Figure 
66). This was not associated with a change in expression of key antioxidant genes, 
namely superoxide dismutase, catalase, and the transcriptional antioxidant regulator Nrf2 
(Figure 67). This suggests that loss of ABCB10 in cardiomyocytes leads to an increase in 
mitochondrial ROS production independently of changes in antioxidant mechanisms. 
5.2.4 CM-specific loss of ABCB10 does not affect cardiac structure or function 
We previously showed that whole body heterozygous loss of ABCB10 has no 
effect on cardiac structure and function. Consistent with those findings, CM-specific 
ABCB10+/- mice had normal cardiac structure and function at 4 months of age. 
Interestingly, homozygous loss of ABCB10 in the cardiomyocyte also had no effect on 
echocardiographic parameters of cardiac structure (wall thickness, end-systolic diameter, 
and end-diastolic diameter) (Figure 68) and function (fractional shortening and wall 
relaxation velocity) (Figure 69) at 4 months of age.  
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Figure 65. CM-ABCB10-/- hearts have unchanged mitochondrial biogenesis and fusion gene 
expression. 
Transcript level of PGC1α, MFN1, and MFN2. N=3. 
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Figure 66. CM-ABCB10-/- hearts have increased complex I-driven ROS production. 
Mitochondrial H2O2 production with complex I (pyruvate and malate) and complex II (succinate with 
rotenone) substrate. N=6. *p<0.05. 
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Figure 67. CM-ABCB10-/- hearts have unchanged antioxidant gene transcript. 
Transcript level of Nrf2, Sod2, and catalase by RT-PCR. N=3. N.s. = not significant. 
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Figure 68. CM-ABCB10+/- and CM-ABCB10-/- mice have unchanged cardiac structure. 
Total wall thickness and end-diastolic diameter (EDD) by echocardiography. N=5. N.s. = not significant. 
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Figure 69. CM-ABCB10+/- and CM-ABCB10-/- mice have unchanged cardiac function. 
Left-ventricular fractional shortening (LV FS) and diastolic tissue relaxation velocity (Em) by 
echocardiography. N=5. N.s. = not significant. 
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5.2.5 CM-ABCB10+/- have decreased survival on HFHS diet 
Previous findings suggest that heterozygous loss of ABCB10 can impair cardiac 
function under conditions of increased oxidative stress. In chapter 4, I found that 
mitochondrial oxidative stress plays a key role in HFHS-induced cardiac dysfunction. 
Thus, I examined the effect of HFHS diet on mice with CM-specific heterozygous loss of 
ABCB10. Surprisingly, while gaining a similar amount of weight to WT littermates 
(Figure 70), CM-ABCB10+/- mice had increased mortality on HFHS diet (Figure 71), 
with a median survival of 6.8 months on diet. Additionally, CM-ABCB10+/- mice fed 
CD also appeared to have a slight increase in mortality around 10 months of age (not 
shown). 
5.2.6 CM-ABCB10+/- mice have exaggerated diet-induced cardiac hypertrophy 
Intracellular ROS can activate signaling pathways in the cardiomyocyte to cause 
cardiac hypertrophy, and we previously showed that mice fed HFHS diet have increased 
oxidative stress and develop cardiac hypertrophy. Thus, I examined the effect of 
heterozygous loss of Abcb10 in CM on HFHS-induced cardiac hypertrophy. Indeed, I 
found that after 6 months of HFHS feeding, CM-ABCB10+/- mice exhibited an 
exaggerated increase in total wall thickness by echocardiography relative to wild-type 
littermates on HFHS (Figure 72). Furthermore, upon sacrifice after 8 months of diet, CM-
ABCB10+/- mice had a trend towards increased heart weight (Figure 73). 
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Figure 70. CM-ABCB10+/- mice gain similar weight on HFHS diet. 
Mouse weight gain recorded at 6 months of diet. N=4-6. N.s. = not significant. 
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Figure 71. CM-ABCB10+/- mice have increased mortality on HFHS diet. 
ABCB10+/- mice have decreased survival at 6-8 months of HFHS diet. N=4-10. 
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Figure 72. CM-ABCB10+/- mice have increased cardiac wall thickness after HFHS diet. 
ABCB10+/- mice have increased total wall thickness with HFHS diet relative to WT littermates. N=4-6. 
*** = p<0.0001 vs WT CD. ## = p<0.001 vs WT HFHS. 
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Figure 73. CM-ABCB10+/- mice may have increased heart weight after HFHS diet. 
ABCB10+/- mice have a trend towards increased heart weight at sacrifice with HFHS diet relative to WT 
HFHS littermates. N=3-5.  
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5.2.7 CM-ABCB10+/- have exaggerated diet-induced diastolic dysfunction 
HFHS diet leads to impairment of cardiac diastolic dysfunction, which is 
prevented with attenuation of mitochondrial dysfunction and ROS production. In CM-
ABCB10+/- mice, I found that 6 months of HFHS diet led to a decrease in the rate of 
relaxation of the ventricular myocardium (Em) relative to WT littermates (Figure 74), 
while fractional shortening, a measure of systolic function, was unchanged (Figure 75). 
5.2.8 CM-ABCB10+/- have similar mitochondrial dysfunction and ROS production 
after HFHS diet 
Whole-body heterozygous loss of ABCB10 exacerbates ischemia-induced 
mitochondrial dysfunction in the heart via increased oxidative stress. I previously showed 
that mice fed HFHS diet develop cardiac mitochondrial dysfunction driven in part by 
oxidative stress. Thus, I examined if CM-ABCB10+/- mice would display an 
exaggeration of HFHS-induced mitochondrial dysfunction and ROS production. 
Surprisingly, among mice fed control diet, CM-ABCB10+/- mice had increased H2O2 
production (Figure 76, Figure 77) and decreased oxygen consumption (Figure 78), but 
similar rates ATP synthesis (Figure 79, Figure 80). On the other hand, in HFHS-fed mice, 
CM-ABCB10+/- mice had lower rates of ROS production, and higher rates of ATP 
synthesis and oxygen consumption than HFHS-fed WT littermates. This suggests that 
partial loss of Abcb10 in the heart may increase mitochondrial ROS production without 
impairing mitochondrial ATP synthesis at baseline, and that HFHS diet is not synergistic. 
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Figure 74. CM-ABCB10+/- mice have decreased diastolic relaxation velocity after HFHS diet. 
ABCB10+/- mice have decreased left-ventricular diastolic relaxation velocity with HFHS diet relative to 
WT littermates. N=4-6. *** = p<0.0001 vs WT CD. ## = p<0.001 vs WT HFHS. 
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Figure 75. WT and CM-ABCB10+/- mice have unchanged systolic function after HFHS diet. 
ABCB10+/- mice have unchanged systolic fractional shortening with HFHS diet relative to WT littermates. 
N=4-6. N.S. = not significant. 
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Figure 76. CM-ABCB10+/- mice have increased mitochondrial ROS production with complex I 
substrates. 
Mitochondria from CM-ABCB10+/- mice have increased ROS production relative to WT littermates on 
both CD and HFHS diet. N=4-6. *** = p<0.0001 vs WT CD. * = p<0.05 vs WT CD. # = <<0.05 vs 
ABCB10+/- CD.  
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Figure 77. CM-ABCB10+/- mice have increased mitochondrial ROS production with complex II 
substrates. 
Mitochondria from CM-ABCB10+/- mice have increased ROS production relative to WT littermates on 
both CD and HFHS diet. N=4-6. *** = p<0.0001 vs WT CD. * = p<0.05 vs WT CD.  
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Figure 78. CM-ABCB10+/- mice have a decrease in state III oxygen consumption with complex II 
substrates. 
Mitochondria from CM-ABCB10+/- mice have a decreased state III oxygen consumption rate relative to 
WT littermates on both CD and HFHS diet. N=4-6. * = p<0.05 vs WT CD. # = p<0.05 vs ABCB10+/- CD. 
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Figure 79. CM-ABCB10+/- mice have a similar HFHS-induced decrease in ATP synthesis with 
complex I substrates. 
Mitochondria from CM-ABCB10+/- mice have a decreased ATP synthesis rate relative to WT littermates 
on both CD and HFHS diet. N=4-6. * = p<0.05 vs WT CD. # = p<0.05 vs ABCB10+/- CD. 
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Figure 80. CM-ABCB10+/- mice have a similar HFHS-induced decrease in ATP synthesis with 
complex II substrates. 
Mitochondria from CM-ABCB10+/- mice have a decreased ATP synthesis rate relative to WT littermates 
on both CD and HFHS diet. N=4-6. * = p<0.05 vs WT CD. # = p<0.05 vs ABCB10+/- CD. 
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5.3 Discussion 
In chapter 4, I found that mice fed HFHS diet develop mitochondrial dysfunction 
characterized by decreased oxygen consumption and ATP synthesis and increased ROS 
production. This appeared to be driven in part by oxidative modification of ETC proteins, 
and attenuation of ROS in mitochondria by catalase overexpression prevented HFHS- 
induced mitochondrial dysfunction and cardiac remodeling. These findings highlighted a 
role of mitochondrial oxidative stress and dysfunction in the pathophysiology of MHD. 
This study expands upon those findings with a number of key observations. First, 
loss of the mitochondrial transport protein ABCB10 in the cardiomyocyte leads to an 
increase in mitochondrial ROS production and a decrease in oxygen consumption without 
changing ATP synthesis and with no adverse effect on cardiac structure, contraction, or 
relaxation at 4 months of age. In the setting of HFHS feeding, where oxidant production 
is pathologically increased, a 50% decrease in Abcb10 in cardiomyocytes is detrimental 
to survival and exacerbates cardiac remodeling without further impairing mitochondrial 
function or ROS production. 
5.3.1 ABCB10: Structure, function, and expression 
ABCB10 is targeted to the inner mitochondrial membrane via a mitochondrial 
targeting sequence. Its substrate is not yet known, but several lines of evidence from 
orthologues in yeast (MDL1) and C. elegans (haf-1, haf-3) suggest that it likely exports 
peptides from the mitochondrial matrix to the inter-membrane space, and its loss would 
lead to mitochondrial dysfunction under stress conditions, either directly (by preventing 
export of damaging peptides) or indirectly (by preventing a signal to communicate with 
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other cellular compartments to mediate a stress response). ABCB10 expression is highest 
in the heart, brain, liver, and hematopoetic tissues, and loss-of-function studies have 
suggested roles for ABCB10 in both protection from oxidative stress and regulation of 
heme and iron metabolism. It is conceivable that both proposed functions are related, as 
heme metabolism produces oxidants, which would require some mitochondrial 
detoxification. 
Whole body loss-of-function studies of ABCB10 have been complicated by 
lethality. In this study, cardiomyocyte-specific ABCB10 gene knockout expands upon 
previous findings. Decreased mitochondrial respiration in CM-ABCB10-/- hearts 
suggests a role in maintaining mitochondrial energetic function at baseline, but appears to 
be a compensated decrease in oxygen consumption as evidenced by the unchanged ATP 
synthesis (similar to the FATP1 model. See section 3.2.5). Additionally, the dramatic 
effect of heterozygous CM-specific loss of ABCB10 on HFHS diet-induced cardiac 
remodeling and survival suggests a key protective function of Abcb10. While the 
mechanism by which ABCB10 loss exaggerates MHD remains unclear, these findings 
justify future in-depth studies of Abcb10 function in the heart. 
5.3.2 Decreased survival in HFHS-fed CM-ABCB10+/- mice 
The increased mortality of CM-ABCB10+/- mice after 7 months of HFHS diet 
was a surprising finding. Echocardiography 1 month prior revealed an exaggerated 
cardiac phenotype of diastolic dysfunction and left-ventricular hypertrophy in HFHS-fed 
CM-ABCB10+/- mice. However, there was no evidence of systolic dysfunction, which is 
a finding typically associated with increased mortality. While the cause of death in these 
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mice is at present unknown, the cardiac-specificity of ABCB10 loss and the sudden 
mortality with no preceding signs or symptoms suggest sudden cardiac death as a 
potential cause. Additionally, there were incidental findings of left-atrial thrombi in some 
ABCB10+/- HFHS mice upon sacrifice, which can form in the setting of cardiac 
arrhythmia. While this remains to be validated in future studies, it may suggest a role for 
cardiac arrhythmias in the early mortality of HFHS-fed ABCB10+/- mice. 
5.3.3 Role of ABCB10 in response to HFHS 
In chapter 4, I found that HFHS-induced cardiac remodeling was associated with 
increased mitochondrial ROS production and mitochondrial dysfunction, and that 
overexpression of a mitochondrial-targeted antioxidant prevented cardiac remodeling and 
mitochondrial dysfunction. Due to the whole-body overexpression of catalase in MCAT 
mice, it was unclear if ROS overproduction in the cardiomyocyte, per se, was responsible 
for the cardiac remodeling, or if the prevention of MHD was secondary to changes 
elsewhere in the body. Here, I present evidence that a 50% decrease in Abcb10 
expression in the cardiomyocyte results in an exaggeration of diet-induced cardiac 
remodeling, likely via an increase in mitochondrial oxidative stress. While the ROS-
dependence of MHD in CM-ABCB10+/- mice is still unproven, this is supported by the 
known protective effect of the catalytic antioxidant compound EUK-207 on 
ischemia/reperfusion-driven dysfunction in whole body ABCB10+/- hearts. Isolated 
mitochondria from control diet-fed CM-ABCB10+/- mice exhibited increased ROS 
production relative to WT CD. However, when fed HFHS diet, CM-ABCB10+/- did not 
have an increase in mitochondrial ROS production relative to WT HFHS and CM-
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ABCB10+/- CD. Similarly, there is no additive effect on the ATP synthesis rate, which is 
slightly less depressed in CM-ABCB10+/- mice, or on the oxygen consumption rate, 
which is markedly increased in CM-ABCB10+/- mice. It is worth noting that the 
mitochondrial studies were only conducted on the CM-ABCB10+/- mice, which survived 
after 7 months of HFHS diet. Thus, the discrepancy between echocardiographic findings 
and mitochondrial function may be explained by a selection bias. Alternatively, ABCB10 
may affect cardiac structure and function independently of an effect on mitochondrial 
function and ROS production. Taken together, these findings suggest a role for ABCB10 
in controlling the cardiac phenotype after HFHS diet, without further affecting the rates 
of mitochondrial ROS and ATP synthesis. 
 
	  	  
131 
BIBLIOGRAPHY 
Anderson, E. J., Kypson, A. P., Rodriguez, E., Anderson, C. A., Lehr, E. J., & Neufer, P. 
D. (2009). Substrate-specific derangements in mitochondrial metabolism and redox 
balance in the atrium of the type 2 diabetic human heart. Journal of the American 
College of Cardiology, 54(20), 1891–1898. doi:10.1016/j.jacc.2009.07.031 
Aon, M. A., Stanley, B. A., Sivakumaran, V., Kembro, J. M., O'Rourke, B., Paolocci, N., 
& Cortassa, S. (2012). Glutathione/thioredoxin systems modulate mitochondrial 
H2O2 emission: an experimental-computational study. The Journal of General 
Physiology, 139(6), 479–491. doi:10.1085/jgp.201210772 
Aubert, G., Vega, R. B., & Kelly, D. P. (2013). Perturbations in the gene regulatory 
pathways controlling mitochondrial energy production in the failing heart. 
Biochimica Et Biophysica Acta (BBA) - Molecular Cell Research, 1833(4), 840–847. 
doi:10.1016/j.bbamcr.2012.08.015 
Barger, P. M., Brandt, J. M., Leone, T. C., Weinheimer, C. J., & Kelly, D. P. (2000). 
Deactivation of peroxisome proliferator-activated receptor-alpha during cardiac 
hypertrophic growth. The Journal of Clinical Investigation, 105(12), 1723–1730. 
doi:10.1172/JCI9056 
Behring, J. B., Kumar, V., Whelan, S. A., Chauhan, P., Siwik, D. A., Costello, C. E., et 
al. (2014). Does reversible cysteine oxidation link the Western diet to cardiac 
dysfunction? FASEB Journal : Official Publication of the Federation of American 
Societies for Experimental Biology, 28(5), 1975–1987. doi:10.1096/fj.13-233445 
Boudina, S., & Abel, E. D. (2006). Mitochondrial uncoupling: a key contributor to 
	  	  
132 
reduced cardiac efficiency in diabetes. Physiology (Bethesda, Md.), 21, 250–258. 
doi:10.1152/physiol.00008.2006 
Boudina, S., & Abel, E. D. (2007). Diabetic Cardiomyopathy Revisited. Circulation, 
115(25), 3213–3223. doi:10.1161/CIRCULATIONAHA.106.679597 
Boudina, S., Sena, S., O'Neill, B. T., Tathireddy, P., Young, M. E., & Abel, E. D. (2005). 
Reduced mitochondrial oxidative capacity and increased mitochondrial uncoupling 
impair myocardial energetics in obesity. Circulation, 112(17), 2686–2695. 
doi:10.1161/CIRCULATIONAHA.105.554360 
Boudina, S., Sena, S., Theobald, H., Sheng, X., Wright, J. J., Hu, X. X., et al. (2007). 
Mitochondrial energetics in the heart in obesity-related diabetes: direct evidence for 
increased uncoupled respiration and activation of uncoupling proteins. Diabetes, 
56(10), 2457–2466. doi:10.2337/db07-0481 
Cai, L., Wang, Y., Zhou, G., Chen, T., Song, Y., Li, X., & Kang, Y. J. (2006). 
Attenuation by metallothionein of early cardiac cell death via suppression of 
mitochondrial oxidative stress results in a prevention of diabetic cardiomyopathy. 
Journal of the American College of Cardiology, 48(8), 1688–1697. 
doi:10.1016/j.jacc.2006.07.022 
Campbell, F. M., Kozak, R., Wagner, A., Altarejos, J. Y., Dyck, J. R. B., Belke, D. D., et 
al. (2002). A role for peroxisome proliferator-activated receptor alpha (PPARalpha ) 
in the control of cardiac malonyl-CoA levels: reduced fatty acid oxidation rates and 
increased glucose oxidation rates in the hearts of mice lacking PPARalpha are 
associated with higher concentrations of malonyl-CoA and reduced expression of 
	  	  
133 
malonyl-CoA decarboxylase. The Journal of Biological Chemistry, 277(6), 4098–
4103. doi:10.1074/jbc.M106054200 
Chan, M. C., & Arany, Z. (2014). The many roles of PGC-1α in muscle - recent 
developments. Metabolism: Clinical and Experimental, 63(4), 441–451. 
doi:10.1016/j.metabol.2014.01.006 
Chance, B., Sies, H., & Boveris, A. (1979). Hydroperoxide metabolism in mammalian 
organs. Physiological Reviews, 59(3), 527–605. 
Chen, J.-Q., Cammarata, P. R., Baines, C. P., & Yager, J. D. (2009). Regulation of 
mitochondrial respiratory chain biogenesis by estrogens/estrogen receptors and 
physiological, pathological and pharmacological implications. Biochimica Et 
Biophysica Acta, 1793(10), 1540–1570. doi:10.1016/j.bbamcr.2009.06.001 
Chen, L., & Knowlton, A. A. (2011). Mitochondrial dynamics in heart failure. Congestive 
Heart Failure (Greenwich, Conn.), 17(6), 257–261. 
Chiu, H. C. (2005). Transgenic expression of fatty acid transport protein 1 in the heart 
causes lipotoxic cardiomyopathy. Circulation Research, 96(2), 225–233. 
doi:10.1161/01.RES.0000154079.20681.B9 
Chiu, H. C., Kovacs, A., Blanton, R. M., Han, X., Courtois, M., Weinheimer, C. J., et al. 
(2005). Transgenic expression of fatty acid transport protein 1 in the heart causes 
lipotoxic cardiomyopathy, 96(2), 225–233. 
doi:10.1161/01.RES.0000154079.20681.B9 
Chiu, H. C., Kovacs, A., Ford, D. A., Hsu, F. F., Garcia, R., Herrero, P., et al. (2001). A 
novel mouse model of lipotoxic cardiomyopathy. The Journal of Clinical 
	  	  
134 
Investigation, 107(7), 813–822. doi:10.1172/JCI10947 
Dabkowski, E. R., Baseler, W. A., Williamson, C. L., Powell, M., Razunguzwa, T. T., 
Frisbee, J. C., & Hollander, J. M. (2010). Mitochondrial dysfunction in the type 2 
diabetic heart is associated with alterations in spatially distinct mitochondrial 
proteomes. AJP: Heart and Circulatory Physiology, 299(2), H529–H540. 
doi:10.1152/ajpheart.00267.2010 
Dai, D.-F., & Rabinovitch, P. (2011). Mitochondrial oxidative stress mediates induction 
of autophagy and hypertrophy in angiotensin-II treated mouse hearts. Autophagy, 
7(8), 917–918. 
Dai, D.-F., Hsieh, E. J., Liu, Y., Chen, T., Beyer, R. P., Chin, M. T., et al. (2012). 
Mitochondrial proteome remodelling in pressure overload-induced heart failure: the 
role of mitochondrial oxidative stress. Cardiovascular Research, 93(1), 79–88. 
doi:10.1093/cvr/cvr274 
Dai, D.-F., Santana, L. F., Vermulst, M., Tomazela, D. M., Emond, M. J., MacCoss, M. 
J., et al. (2009). Overexpression of catalase targeted to mitochondria attenuates 
murine cardiac aging. Circulation, 119(21), 2789–2797. 
doi:10.1161/CIRCULATIONAHA.108.822403 
Din, S., Mason, M., Völkers, M., Johnson, B., Cottage, C. T., Wang, Z., et al. (2013). 
Pim-1 preserves mitochondrial morphology by inhibiting dynamin-related protein 1 
translocation. Proceedings of the National Academy of Sciences of the United States 
of America, 110(15), 5969–5974. doi:10.1073/pnas.1213294110 
Dong, F., Li, Q., Sreejayan, N., Nunn, J. M., & Ren, J. (2007). Metallothionein prevents 
	  	  
135 
high-fat diet induced cardiac contractile dysfunction: role of peroxisome proliferator 
activated receptor gamma coactivator 1alpha and mitochondrial biogenesis. Diabetes, 
56(9), 2201–2212. doi:10.2337/db06-1596 
Dorn, G. W., II. (2013). Mitochondrial dynamics in heart disease. Biochimica Et 
Biophysica Acta (BBA) - Molecular Cell Research, 1833(1), 233–241. 
doi:10.1016/j.bbamcr.2012.03.008 
Drosatos, K., Bharadwaj, K. G., Lymperopoulos, A., Ikeda, S., Khan, R., Hu, Y., et al. 
(2011). Cardiomyocyte lipids impair β-adrenergic receptor function via PKC 
activation. American Journal of Physiology. Endocrinology and Metabolism, 300(3), 
E489–99. doi:10.1152/ajpendo.00569.2010 
Duncan, J. G. (2011). Peroxisome proliferator activated receptor-alpha (PPARα) and 
PPAR gamma coactivator-1alpha (PGC-1α) regulation of cardiac metabolism in 
diabetes. Pediatric Cardiology, 32(3), 323–328. doi:10.1007/s00246-011-9889-8 
Fan, M., Sidhu, R., Fujiwara, H., Tortelli, B., Zhang, J., Davidson, C., et al. (2013). 
Identification of Niemann-Pick C1 disease biomarkers through sphingolipid 
profiling. Journal of Lipid Research, 54(10), 2800–2814. doi:10.1194/jlr.M040618 
Finck, B. N., & Kelly, D. P. (2007). Peroxisome proliferator-activated receptor gamma 
coactivator-1 (PGC-1) regulatory cascade in cardiac physiology and disease. 
Circulation, 115(19), 2540–2548. doi:10.1161/CIRCULATIONAHA.107.670588 
Finck, B. N., Han, X., Courtois, M., Aimond, F., Nerbonne, J. M., Kovacs, A., et al. 
(2003). A critical role for PPARalpha-mediated lipotoxicity in the pathogenesis of 
diabetic cardiomyopathy: modulation by dietary fat content. Proceedings of the 
	  	  
136 
National Academy of Sciences of the United States of America, 100(3), 1226–1231. 
doi:10.1073/pnas.0336724100 
Finck, B. N., Lehman, J. J., Leone, T. C., (null), (null), Kovacs, A., et al. (2002). The 
cardiac phenotype induced by PPARalpha overexpression mimics that caused by 
diabetes mellitus. The Journal of Clinical Investigation, 109(1), 10. 
García-Rúa, V., Otero, M. F., Lear, P. V., Rodríguez-Penas, D., Feijóo-Bandín, S., 
Noguera-Moreno, T., et al. (2012). Increased expression of fatty-acid and calcium 
metabolism genes in failing human heart. PLoS ONE, 7(6), e37505. 
doi:10.1371/journal.pone.0037505 
Ge, F., Hu, C., Hyodo, E., Arai, K., Zhou, S., Lobdell, H., et al. (2012). Cardiomyocyte 
triglyceride accumulation and reduced ventricular function in mice with obesity 
reflect increased long chain Fatty Acid uptake and de novo Fatty Acid synthesis. 
Journal of Obesity, 2012, 205648. doi:10.1155/2012/205648 
Ghosh, S., & Rodrigues, B. (2006). Cardiac cell death in early diabetes and its 
modulation by dietary fatty acids. Biochimica Et Biophysica Acta, 1761(10), 1148–
1162. doi:10.1016/j.bbalip.2006.08.010 
Gibbs, C. L. (1978). Cardiac energetics. Physiological Reviews, 58(1), 174–254. 
Goldberg, I. J., Trent, C. M., & Schulze, P. C. (2012). Lipid Metabolism and Toxicity in 
the Heart. Cell Metabolism, 15(6), 805–812. doi:10.1016/j.cmet.2012.04.006 
Hafstad, A. D., Lund, J., Hadler-Olsen, E., Höper, A. C., Larsen, T. S., & Aasum, E. 
(2013). High- and moderate-intensity training normalizes ventricular function and 
mechanoenergetics in mice with diet-induced obesity. Diabetes, 62(7), 2287–2294. 
	  	  
137 
doi:10.2337/db12-1580 
Herzig, S., Long, F., Jhala, U. S., Hedrick, S., Quinn, R., Bauer, A., et al. (2001). CREB 
regulates hepatic gluconeogenesis through the coactivator PGC-1. Nature, 
413(6852), 179–183. doi:10.1038/35093131 
Hoffman, D. L., & Brookes, P. S. (2009). Oxygen sensitivity of mitochondrial reactive 
oxygen species generation depends on metabolic conditions. The Journal of 
Biological Chemistry, 284(24), 16236–16245. doi:10.1074/jbc.M809512200 
Huss, J. M., Kopp, R. P., & Kelly, D. P. (2002). Peroxisome proliferator-activated 
receptor coactivator-1alpha (PGC-1alpha) coactivates the cardiac-enriched nuclear 
receptors estrogen-related receptor-alpha and -gamma. Identification of novel 
leucine-rich interaction motif within PGC-1alpha. The Journal of Biological 
Chemistry, 277(43), 40265–40274. doi:10.1074/jbc.M206324200 
Huss, J. M., Torra, I. P., Staels, B., Giguère, V., & Kelly, D. P. (2004). Estrogen-related 
receptor alpha directs peroxisome proliferator-activated receptor alpha signaling in 
the transcriptional control of energy metabolism in cardiac and skeletal muscle. 
Molecular and Cellular Biology, 24(20), 9079–9091. doi:10.1128/MCB.24.20.9079-
9091.2004 
Kenchaiah, S., Evans, J. C., Levy, D., Wilson, P. W. F., Benjamin, E. J., Larson, M. G., 
et al. (2002). Obesity and the risk of heart failure. The New England Journal of 
Medicine, 347(5), 305–313. doi:10.1056/NEJMoa020245 
Las, G., Serada, S. B., Wikstrom, J. D., Twig, G., & Shirihai, O. S. (2011). Fatty acids 
suppress autophagic turnover in β-cells. The Journal of Biological Chemistry, 
	  	  
138 
286(49), 42534–42544. doi:10.1074/jbc.M111.242412 
Lavie, C. J., Alpert, M. A., Arena, R., Mehra, M. R., Milani, R. V., & Ventura, H. O. 
(2013). Impact of obesity and the obesity paradox on prevalence and prognosis in 
heart failure. JACC. Heart Failure, 1(2), 93–102. doi:10.1016/j.jchf.2013.01.006 
Lavie, C. J., Milani, R. V., & Ventura, H. O. (2009). Obesity and cardiovascular disease: 
risk factor, paradox, and impact of weight loss. Journal of the American College of 
Cardiology, 53(21), 1925–1932. doi:10.1016/j.jacc.2008.12.068 
Lee, H.-Y., Choi, C. S., Birkenfeld, A. L., Alves, T. C., Jornayvaz, F. R., Jurczak, M. J., 
et al. (2010). Targeted expression of catalase to mitochondria prevents age-associated 
reductions in mitochondrial function and insulin resistance. Cell Metabolism, 12(6), 
668–674. doi:10.1016/j.cmet.2010.11.004 
Lehman, J. J., Barger, P. M., Kovacs, A., Saffitz, J. E., Medeiros, D. M., & Kelly, D. P. 
(2000). Peroxisome proliferator-activated receptor gamma coactivator-1 promotes 
cardiac mitochondrial biogenesis. The Journal of Clinical Investigation, 106(7), 847–
856. doi:10.1172/JCI10268 
Leichman, J. G., Aguilar, D., King, T. M., Vlada, A., Reyes, M., & Taegtmeyer, H. 
(2006). Association of plasma free fatty acids and left ventricular diastolic function 
in patients with clinically severe obesity. The American Journal of Clinical Nutrition, 
84(2), 336–341. 
Li, F. C. H., Yen, J.-C., Chan, S. H. H., & Chang, A. Y. W. (2012). Bioenergetics failure 
and oxidative stress in brain stem mediates cardiovascular collapse associated with 
fatal methamphetamine intoxication. PLoS ONE, 7(1), e30589. 
	  	  
139 
doi:10.1371/journal.pone.0030589 
Li, Y., He, L., Zeng, N., Sahu, D., Cadenas, E., Shearn, C., et al. (2013). Phosphatase and 
tensin homolog deleted on chromosome 10 (PTEN) signaling regulates mitochondrial 
biogenesis and respiration via estrogen-related receptor α (ERRα). The Journal of 
Biological Chemistry, 288(35), 25007–25024. doi:10.1074/jbc.M113.450353 
Liang, Q., Carlson, E. C., Donthi, R. V., Kralik, P. M., Shen, X., & Epstein, P. N. (2002). 
Overexpression of metallothionein reduces diabetic cardiomyopathy. Diabetes, 51(1), 
174–181. 
Liesa, M., Luptak, I., Qin, F., Hyde, B. B., Sahin, E., Siwik, D. A., et al. (2011). 
Mitochondrial Transporter ATP Binding Cassette Mitochondrial Erythroid Is a Novel 
Gene Required for Cardiac Recovery After Ischemia/Reperfusion. Circulation, 
124(7), 806–813. doi:10.1161/CIRCULATIONAHA.110.003418 
Lopaschuk, G. D., Ussher, J. R., Folmes, C. D. L., Jaswal, J. S., & Stanley, W. C. (2010). 
Myocardial fatty acid metabolism in health and disease. Physiological Reviews, 
90(1), 207–258. doi:10.1152/physrev.00015.2009 
Main, M. L., Rao, S. C., & O'Keefe, J. H. (2010). Trends in obesity and extreme obesity 
among US adults. JAMA : the Journal of the American Medical Association, 303(17), 
1695–author reply 1695–6. doi:10.1001/jama.2010.517 
Mansouri, A., Muller, F. L., Liu, Y., Ng, R., Faulkner, J., Hamilton, M., et al. (2006). 
Alterations in mitochondrial function, hydrogen peroxide release and oxidative 
damage in mouse hind-limb skeletal muscle during aging. Mechanisms of Ageing and 
Development, 127(3), 298–306. doi:10.1016/j.mad.2005.11.004 
	  	  
140 
Martin, O. J., Lai, L., Soundarapandian, M. M., Leone, T. C., Zorzano, A., Keller, M. P., 
et al. (2014). A Role for Peroxisome Proliferator-Activated Receptor γ Coactivator-1 
in the Control of Mitochondrial Dynamics During Postnatal Cardiac Growth. 
Circulation Research, 114(4), 626–636. doi:10.1161/CIRCRESAHA.114.302562 
Mehta, K. D. (2014). Emerging role of protein kinase C in energy homeostasis: A brief 
overview. World Journal of Diabetes, 5(3), 385–392. doi:10.4239/wjd.v5.i3.385 
Molina, A. J. A., Wikstrom, J. D., Stiles, L., Las, G., Mohamed, H., Elorza, A., et al. 
(2009). Mitochondrial networking protects beta-cells from nutrient-induced 
apoptosis. Diabetes, 58(10), 2303–2315. doi:10.2337/db07-1781 
Motley, E. D., Kabir, S. M., Eguchi, K., Hicks, A. L., Gardner, C. D., Reynolds, C. M., et 
al. (2001). Protein kinase C inhibits insulin-induced Akt activation in vascular 
smooth muscle cells. Cellular and Molecular Biology (Noisy-Le-Grand, France), 
47(6), 1059–1062. 
Muller, F. L., Liu, Y., Abdul-Ghani, M. A., Lustgarten, M. S., Bhattacharya, A., Jang, Y. 
C., & Van Remmen, H. (2008). High rates of superoxide production in skeletal-
muscle mitochondria respiring on both complex I- and complex II-linked substrates. 
Biochemical Journal, 409(2), 491–499. doi:10.1042/BJ20071162 
Murphy, M. P. (2009). How mitochondria produce reactive oxygen species. Biochemical 
Journal, 417(1), 1–13. doi:10.1042/BJ20081386 
Neubauer, S. (2007). The failing heart--an engine out of fuel. The New England Journal 
of Medicine, 356(11), 1140–1151. doi:10.1056/NEJMra063052 
Nowak, G., Bakajsova, D., & Samarel, A. M. (2011). Protein kinase C-epsilon activation 
	  	  
141 
induces mitochondrial dysfunction and fragmentation in renal proximal tubules. 
American Journal of Physiology. Renal Physiology, 301(1), F197–208. 
doi:10.1152/ajprenal.00364.2010 
Parra, V., Verdejo, H. E., Iglewski, M., Del Campo, A., Troncoso, R., Jones, D., et al. 
(2014). Insulin stimulates mitochondrial fusion and function in cardiomyocytes via 
the Akt-mTOR-NFκB-Opa-1 signaling pathway. Diabetes, 63(1), 75–88. 
doi:10.2337/db13-0340 
Patergnani, S., Marchi, S., Rimessi, A., Bonora, M., Giorgi, C., Mehta, K. D., & Pinton, 
P. (2013). PRKCB/protein kinase C, beta and the mitochondrial axis as key 
regulators of autophagy. Autophagy, 9(9), 1367–1385. doi:10.4161/auto.25239 
Pimentel, D. R., Adachi, T., Ido, Y., Heibeck, T., Jiang, B., Lee, Y., et al. (2006). Strain-
stimulated hypertrophy in cardiac myocytes is mediated by reactive oxygen species-
dependent Ras S-glutathiolation. Journal of Molecular and Cellular Cardiology, 
41(4), 613–622. doi:10.1016/j.yjmcc.2006.05.009 
Qin, F., Siwik, D. A., Luptak, I., Hou, X., Wang, L., Higuchi, A., et al. (2012). The 
polyphenols resveratrol and S17834 prevent the structural and functional sequelae of 
diet-induced metabolic heart disease in mice. Circulation, 125(14), 1757–64– S1–6. 
doi:10.1161/CIRCULATIONAHA.111.067801 
Ren, J., Pulakat, L., Whaley-Connell, A., & Sowers, J. R. (2010). Mitochondrial 
biogenesis in the metabolic syndrome and cardiovascular disease. Journal of 
Molecular Medicine, 88(10), 993–1001. doi:10.1007/s00109-010-0663-9 
Rider, O. J., Francis, J. M., Ali, M. K., Holloway, C., Pegg, T., Robson, M. D., et al. 
	  	  
142 
(2012). Effects of catecholamine stress on diastolic function and myocardial 
energetics in obesity. Circulation, 125(12), 1511–1519. 
doi:10.1161/CIRCULATIONAHA.111.069518 
Rider, O. J., Francis, J. M., Tyler, D., Byrne, J., Clarke, K., & Neubauer, S. (2013). 
Effects of weight loss on myocardial energetics and diastolic function in obesity. The 
International Journal of Cardiovascular Imaging, 29(5), 1043–1050. 
doi:10.1007/s10554-012-0174-6 
Roger, V. L. (2013). Epidemiology of heart failure. Circulation Research, 113(6), 646–
659. doi:10.1161/CIRCRESAHA.113.300268 
Sahin, E., Colla, S., Liesa, M., Moslehi, J., Muller, F. L., Guo, M., et al. (2011). 
Telomere dysfunction induces metabolic and mitochondrial compromise. Nature, 
470(7334), 359–365. doi:10.1038/nature09787 
Sawyer, D. B., Siwik, D. A., Xiao, L., Pimentel, D. R., Singh, K., & Colucci, W. S. 
(2002). Role of oxidative stress in myocardial hypertrophy and failure. Journal of 
Molecular and Cellular Cardiology, 34(4), 379–388. doi:10.1006/jmcc.2002.1526 
Scarpulla, R. C. (2008). Transcriptional paradigms in mammalian mitochondrial 
biogenesis and function. Physiological Reviews, 88(2), 611–638. 
doi:10.1152/physrev.00025.2007 
Schriner, S. E., Linford, N. J., Martin, G. M., Treuting, P., Ogburn, C. E., Emond, M., et 
al. (2005). Extension of murine life span by overexpression of catalase targeted to 
mitochondria. Science (New York, N.Y.), 308(5730), 1909–1911. 
doi:10.1126/science.1106653 
	  	  
143 
Sharma, K., & Kass, D. A. (2014). Heart failure with preserved ejection fraction: 
mechanisms, clinical features, and therapies. Circulation Research, 115(1), 79–96. 
doi:10.1161/CIRCRESAHA.115.302922 
Sharma, S., Adrogue, J. V., Golfman, L., Uray, I., Lemm, J., Youker, K., et al. (2004). 
Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic 
rat heart. FASEB Journal : Official Publication of the Federation of American 
Societies for Experimental Biology, 18(14), 1692–1700. doi:10.1096/fj.04-2263com 
Shen, X., Zheng, S., Metreveli, N. S., & Epstein, P. N. (2006). Protection of cardiac 
mitochondria by overexpression of MnSOD reduces diabetic cardiomyopathy. 
Diabetes, 55(3), 798–805. 
Soriano, F. X., Liesa, M., Bach, D., Chan, D. C., Palacín, M., & Zorzano, A. (2006). 
Evidence for a mitochondrial regulatory pathway defined by peroxisome proliferator-
activated receptor-gamma coactivator-1 alpha, estrogen-related receptor-alpha, and 
mitofusin 2. Diabetes, 55(6), 1783–1791. doi:10.2337/db05-0509 
Sverdlov, A. L., Elezaby, A., Behring, J. B., Bachschmid, M. M., Luptak, I., Tu, V. H., et 
al. (2014). High fat, high sucrose diet causes cardiac mitochondrial dysfunction due 
in part to oxidative post-translational modification of mitochondrial complex II. 
Journal of Molecular and Cellular Cardiology. doi:10.1016/j.yjmcc.2014.07.018 
Takimoto, E., Champion, H. C., Li, M., Ren, S., Rodriguez, E. R., Tavazzi, B., et al. 
(2005). Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac 
pathologic remodeling from chronic pressure load. The Journal of Clinical 
Investigation, 115(5), 1221–1231. doi:10.1172/JCI21968 
	  	  
144 
Tocchetti, C. G., Caceres, V., Stanley, B. A., Xie, C., Shi, S., Watson, W. H., et al. 
(2012). GSH or palmitate preserves mitochondrial energetic/redox balance, 
preventing mechanical dysfunction in metabolically challenged myocytes/hearts from 
type 2 diabetic mice. Diabetes, 61(12), 3094–3105. doi:10.2337/db12-0072 
van der Vusse, G. J., Glatz, J. F., Stam, H. C., & Reneman, R. S. (1992). Fatty acid 
homeostasis in the normoxic and ischemic heart. Physiological Reviews, 72(4), 881–
940. 
van der Vusse, G. J., van Bilsen, M., & Glatz, J. F. (2000). Cardiac fatty acid uptake and 
transport in health and disease. Cardiovascular Research, 45(2), 279–293. 
Vega, R. B., Huss, J. M., & Kelly, D. P. (2000). The coactivator PGC-1 cooperates with 
peroxisome proliferator-activated receptor alpha in transcriptional control of nuclear 
genes encoding mitochondrial fatty acid oxidation enzymes. Molecular and Cellular 
Biology, 20(5), 1868–1876. 
Vork, M. M., Glatz, J. F., & van der Vusse, G. J. (1993). On the mechanism of long chain 
fatty acid transport in cardiomyocytes as facilitated by cytoplasmic fatty acid-binding 
protein. Journal of Theoretical Biology, 160(2), 207–222. doi:10.1006/jtbi.1993.1014 
Wende, A. R., & Abel, E. D. (2010). Lipotoxicity in the heart. Biochimica Et Biophysica 
Acta (BBA) - Molecular and Cell Biology of Lipids, 1801(3), 311–319. 
doi:10.1016/j.bbalip.2009.09.023 
Yagyu, H., Chen, G., Yokoyama, M., Hirata, K., Augustus, A., Kako, Y., et al. (2003). 
Lipoprotein lipase (LpL) on the surface of cardiomyocytes increases lipid uptake and 
produces a cardiomyopathy. The Journal of Clinical Investigation, 111(3), 419–426. 
	  	  
145 
doi:10.1172/JCI16751 
Ye, G., Metreveli, N. S., Donthi, R. V., Xia, S., Xu, M., Carlson, E. C., & Epstein, P. N. 
(2004). Catalase protects cardiomyocyte function in models of type 1 and type 2 
diabetes. Diabetes, 53(5), 1336–1343. 
Zhang, Y., Yuan, M., Bradley, K. M., Dong, F., Anversa, P., & Ren, J. (2012). Insulin-
like growth factor 1 alleviates high-fat diet-induced myocardial contractile 
dysfunction: role of insulin signaling and mitochondrial function. Hypertension, 
59(3), 680–693. doi:10.1161/HYPERTENSIONAHA.111.181867 
Zhao, T., Huang, X., Han, L., Wang, X., Cheng, H., Zhao, Y., et al. (2012). Central role 
of mitofusin 2 in autophagosome-lysosome fusion in cardiomyocytes. The Journal of 
Biological Chemistry, 287(28), 23615–23625. doi:10.1074/jbc.M112.379164 
Zorzano, A., Liesa, M., Sebastián, D., Segalés, J., & Palacín, M. (2010). Mitochondrial 
fusion proteins: dual regulators of morphology and metabolism. Seminars in Cell & 
Developmental Biology, 21(6), 566–574. doi:10.1016/j.semcdb.2010.01.002 
	   146 
CURRICULUM VITAE 
	  	  
147 
	  	  
148 
	  	  
149 
